FRC Statement on Frist Support for Embryonic Stem Cell Research
FRC Statement on Frist Support for Embryonic Stem Cell Research
Friday July 29, 12:27 pm ET


WASHINGTON, July 29 -- Today, Senate Majority Leader Bill Frist (R-TN) announced on the floor of the Senate his support for public funding of additional human embryo destruction for human embryonic stem cell research and an expansion of President Bush's policy regarding funding of such research. Family Research Council President Tony Perkins released the following statement:

"Senator Frist's announcement is very disappointing but not a surprise. It is reminiscent of the speech he gave to the 2004 Republican platform committee, where he squelched open debate on the ethics of embryonic stem cell research, as well as a 2001 Senate hearing testimony where he advocated production of hundreds of human embryonic stem cell lines, which would have required destruction of thousands of human embryos.

"As a heart surgeon who knows that adult stem cells are already making huge progress in treating heart disease in humans, it is unfortunate that Sen. Frist would capitulate to the biotech industry. Under the current policy, 22 human embryonic stem cell lines, and over 3500 vials of such cells, are available for research; 39 more lines wait in the freezer for researchers to use them, and there is no cap on the federal money available for this research. Yet after 24 years of work with mouse and human embryonic stem cells, this 'promising' research has delivered not a single treatment for human patients and sparse results in mice. Thankfully the White House has forcefully promised to hold the ethical line and veto any legislation that would expand the President's current policy.

"Meanwhile, thousands of patients are better TODAY after umbilical cord blood and adult stem cell treatments for at least 65 conditions, including over 200 heart patients, results of which heart surgeon Dr. Frist should take notice. The progress of adult stem cell research, including evidence that they, too, are pluripotent, is causing many scientists to rethink their support for embryonic stem cell research. Senator Frist, please support good science, good ethics, and good public policy."




--------------------------------------------------------------------------------
Source: Family Research Council


Biotechnology News at Arizona Biotech Arizona Biotech News - BioTech News at Arizona Biotech - Arizona Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Genetic Engineering News Reports on Stem Cell Fact and Fiction

Genetic Engineering News Reports on Stem Cell Fact and Fiction

NEW ROCHELLE, N.Y.

July 13, 2005--Scientists around the world are employing a variety
of methods to translate human stem cell research into bona fide
therapies for a host of diseases, reports Genetic Engineering News
(GEN) (www.genengnews.com). However, technical and, particularly in
the U.S., societal questions need to be addressed before stem cell
technology can reach its full potential, according to the July issue
of GEN.

"The bottom line is that stem cell research is young," says John
Sterling, Editor-in-Chief of GEN. "But this fact is often overlooked
as a result of some of the hype over stem cells and because of the
intense controversy the topic has engendered in a number of
religious and political circles."

While the U.S. is engaged in a debate over reinstituting the use of
federal funds to support new embryonic stem cell research,
scientific matters remain to be resolved. These include gaining more
knowledge about the stages of cellular differentiation, the numbers
of stem cells needed for therapeutic applications and the types of
delivery systems that will be required, the length of time that stem
cells can function in animal models, and the optimal combination of
growth factors and cell culture conditions for stem cells.

Some companies, such as Aastrom Biosciences (NASDAQ:ASTM) and
MultiCell Technologies (NASDAQ:MCET), are working with adult stem
cells. For example, in a clinical trial involving long bone non-
union fractures, all patients treated with Aastrom's tissue repair
cells exhibited both clinical and functional healing and, at six
months, five of the six showed bone regeneration at the fracture
site. MultiCell Technologies won a patent this spring that
incorporates hepatocytes with stem cells that can differentiate into
mature, functioning, hepatocyte or bile duct cells that eventually
may treat degenerative liver diseases or inherited functional
deficiencies in the liver.

Cytori Therapeutics (Frankfurt:XMP), formerly MacroPore Biosurgery,
sees a future in fat, which is an excellent source of stem cells.
The company, which works with large animals at several academic
centers in the U.S. and abroad and, in collaboration with UCLA, with
small animals, has published data showing the benefits of fat-
derived stem cells.

Geron Corp. (NYSE:GERN) demonstrated proof of concept injecting
oligodendrocytes and dopaminergic neurons derived from human
embryonic stem cells directly into injured spinal cords in rats and
found motor improvement. An early study to repopulate heart tissue
was also successful.

Stem cell research at ReNeuron and BioE is also covered in the GEN
article.

Genetic Engineering News is published 21 times a year by Mary Ann
Liebert, Inc.

Arizona Biotech
Biotech News
Biotechnology Forum
Arizona Entrepreneurs
Arizona High Tech
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Genetically Modified Organisms (GMOs) Workshop
Genetically Modified Organisms (GMOs) Workshop

General News of Thursday, 28 July 2005

Workshop on organisms opens
Accra, July 28, GNA - A workshop on Genetically Modified Organisms (GMOs) on Thursday opened in Accra to discuss and debate the benefits and risks in applying the GMOs in various key sectors of Ghana's economy.

Genetically Modified Organisms are genetic engineering tools for producing new varieties and new products in agriculture, health and industry.

The Science and Technology Policy Research Institute (STEPRI) of the Centre for Scientific and Industrial Research (CSIR) is hosting the workshop being attended by stakeholders who would exchange ideas and provide inputs to policy formulation on the application of GMOs in Ghana.

Participants would also address issues of Ghana's effort to take full advantage of genetic engineering, issues of risk management, capacity building and investment.

Professor Emmanuel Owusu Bennoah, Director General, CSIR, said despite the risks involved with any scientific technology, Ghana could take advantage of the GMOs in her agriculture productions to enable her to become food sufficient.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Genetic Engineering of Flowers
Genetic Engineering of Flowers

By Jacquie Kangas
July 28, 2005
My childhood memories are filled with the fragrance of flowers.


American Chronicle: Genetic Engineering of Flowers

How have we allowed genetic engineering of flowers to progress so far that young adults today are not even aware that various flowers once had beautiful fragrances? I am told flowers are being altered to increase their size, colour and bloom time. I haven't noticed that cut flowers last any longer, but some varieties do, indeed, come in stunning new colours, but at what expense?
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] North Carolina Biotechnology Center

North Carolina Biotechnology Center

Triad Group to Release 21 Ideas for Boosting Biotechnology

Lt. Gov. Beverly Perdue to speak at Triad BioNight celebration
tonight

GREENSBORO, N.C., July 14 -- The Advisory Committee for
Biotechnology in the Piedmont Triad will formally release 21
strategic recommendations for strengthening the industry during the
Triad BioNight reception and awards banquet tonight at the O. Henry
Hotel.
The advisory committee, a group of more than two dozen academic and
industry leaders working with the North Carolina Biotechnology
Center, drafted the recommendations to work in tandem with Gov. Mike
Easley's plan New Jobs Across North Carolina: A Strategic Plan for
Growing the Economy Statewide Through Biotechnology.

"A statewide plan for biotechnology is in effect, and now a strong
plan has taken shape that is tailored to the Piedmont Triad region's
needs and effort," said Russ Read, vice chair of the advisory
committee and executive director for the National Center for the
Biotechnology Workforce at Forsyth Technical Community College. "As
a part of the larger concerted effort, this is a most significant
accomplishment for the region and for the continuing effort of
biotechnology economic promotion for all of North Carolina."

The advisory committee's 21 recommendations call for:
- Creating a regional directory of goods manufactured by local
biotechnology companies;
- Building a database of available wet lab space;
- Forming a legislative team to monitor the Triad's
biotechnology
priorities;
- Collecting economic and academic data from primary and
secondary data
sources;
- Hosting a reception dinner to showcase the Triad's
biotechnology
community;
- Partnering with the Council of Entrepreneurial Development to
host
Biotech 2006;
- Developing national and regional public relations and
advertising
campaigns extolling the virtues of the Triad's biotechnology
community;
- Marketing agricultural biotechnology;
- Creating intellectual exchange groups based on scientific
topics;
- Operating databases of university research and intellectual
property
assets;
- Providing more interaction between the Triad's universities
and
industry members;
- Developing innovative training and career programs;
- Creating a Translational Research Center for the central
nervous system
and behavioral sciences;
- Promoting community college programs and develop new ones
based on
industry feedback;
- Determining recruiting needs and the alliances needed to
bring renowned
researchers to the Triad;
- Creating financial packages to support recruitment efforts;
- Forming a welcoming committee for new clients;
- Providing affordable, short-term office/lab space by creating
a "wet-
lab hotel";
- Creating low-cost office space for foreign countries to place
a
regional liaison;
- Forming a team with local partners to recruit contract
manufacturing
companies;
- Attracting entrepreneurs to develop businesses around the
region's
Centers of Excellence like the Institute for Regenerative
Medicine.

The recommendations reflect about 18 months of work for the advisory
committee.

"Through efforts such as those of the Advisory Committee for
Biotechnology in the Piedmont Triad, we are building a community to
support biotechnology that has few equals nationally or
internationally," said Committee Chair Dr. Rosemary Wander,
associate provost for research at the University of North Carolina
at Greensboro.

The next step, said Gwyn Riddick, director of the Piedmont Triad
Office of the Biotechnology Center, is for six project teams
appointed by the advisory committee to begin implementing the 21
recommendations in concert with partner organizations in the
Piedmont Triad.

One of the recommendations will come to fruition tonight when the
Biotechnology Center and 29 other sponsors host the Triad BioNight
celebration, at the O. Henry Hotel, 624 Green Valley Road, in
Greensboro, starting at 6 p.m.

The event will feature a keynote address by Lt. Gov. Beverly Perdue
on biotechnology and the new economy and a networking reception and
awards banquet for the Piedmont Triad's biotechnology community.
Other speakers will include Don deBethizy, CEO of Targacept;
biotechnology entrepreneur Max Wallace, chairman of the Innovation
Foundation and president of The Arbor Group; and Leslie Alexandre,
president and CEO of the Biotechnology Center.

In addition, Gayle Anderson, president of the Winston-Salem Chamber
of Commerce, will give an update on the Triad's biotechnology
assessment and index project.

Five awards will be given to honor the work of key leaders in the
Piedmont Triad's biotechnology community. The awards, and their
recipients, are:

- Research and Development Excellence: Anthony Atala, M.D.,
director,
Institute for Regenerative Medicine, and chair, Department of
Urology,
Wake Forest University Health Sciences
- Entrepreneurial Excellence: Roland H. Johnson, president &
CEO,
Piedmont Pharmaceuticals
- Academic Development Excellence: Gary M. Green, Ed.D.,
president, and
Lucas Shallua, D.Sc., biotechnology program coordinator,
Forsyth
Technical Community College
- Piedmont Biotechnology Community Leadership Excellence: Gwyn
Riddick,
director, Piedmont Triad Office, North Carolina Biotechnology
Center
- Biotechnology Service and Support Excellence: Bill Dean,
president,
!dealliance

The North Carolina Biotechnology Center, headquartered in Research
Triangle Park with satellite offices in Winston-Salem and Asheville,
is a state-supported, non-profit corporation. Its mission is to
provide long-term economic and societal benefits to North Carolina
by supporting biotechnology research, business and education
statewide.

---------------------------------------------------------------------
-----------
Source: North Carolina Biotechnology Center

Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Howrey LLP - United Kingdom - Cambridge Antibody Technology V Abbott Biotechnology Limited (25/07/2005) from Mondaq
Howrey LLP - United Kingdom - Cambridge Antibody Technology V Abbott Biotechnology Limited (25/07/2005) from Mondaq

United Kingdom: Cambridge Antibody Technology V Abbott Biotechnology Limited
Free Weekly Newsletters
Would you like to be kept informed about similar articles? >Signup<



Further information
Give Firm your Feedback

Sign up for a free News Alert

Information contributed by Howrey LLP
View all Articles by this Firm

View summary of all information contributed

View Firm's Website

General links
Email a colleague with a synopsis and link to this article

Printer-friendly version of this page

Become a contributor


Legal Jobs


View Other Articles Classified By:
Intellectual Property

Pharmaceutical, Healthcare & Life Sciences

Biotechnology, Life Sciences & Healthcare

Licensing & Syndication

Patent

Trade Secrets

Arbitration & Dispute Resolution

Commercial

Healthcare/ Medical

Life Sciences & Biotechnology

Patents

25 July 2005
Article by Calum Smyth
In one of the year’s most valuable contract claims to come before the UK Patents Court, the CAT v Abbott dispute demonstrates the importance of properly understanding both the extent of existing IP rights and the nature of the protected technology, when drafting commercial agreements in technically complex fields.

Under two collaboration agreements (the "Agreements") Abbott was licensed to use CAT's patented technology in order to develop an antibody to a protein known as TNFa - a protein thought to play a large part in rheumatoid arthritis. The case concerned a dispute over the amount of royalties payable in relation to Abbott's sales of HUMIRA, a blockbuster biologic rheumatoid arthritis drug that utilises the TNFa antibody....


Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] GOVERNMENT SUPPORTS BIO-TECHNOLOGY DEVELOPMENT

GOVERNMENT SUPPORTS BIO-TECHNOLOGY DEVELOPMENT
---------------------------------------------------------------------
-----------

17:51 IST
Lok Sabha

The Department of Biotechnology provides grant-in-aid support for
research & development, and capacity building in the area of
biotechnology to universities, research institutes and not-for-
profit organizations across the country. In addition grant-in-aid
is also provided for creation of Centers of Excellence in emerging
areas. During the last 5 years more than 2000 R&D Projects have
been supported; 74 universities have been supported for post-
graduate biotechnology programmes, 60 universities and research
institutes have been provided support for bioinformatics network
centers. In addition 57 biotechnology infrastructure facilities
have been established across the country for cutting edge basic
research and process and product development.

To promote excellence in biotechnology it is proposed to
establish Centers of Excellence in the areas of :

Ø Transnational research in public health

Ø Stem Cell
Ø Marine biotechnology

Ø Animal biotechnology
Ø Nutritional genomics and food biotechnology

Ø Herbal Medicine

Ø Molecular medicine
Ø Bio-materials and devices and

Ø Bio-informatics

In addition centers would also be supported in other frontier
emerging areas of Biotechnology.

This information was given by Shri Kapil Sibbal,
Minister of State, Science and Technology and Ocean Development in
Lok Sabha today.

Biotech in Arizona
Biotechnology News
Entrepreneurs in Arizona
High Tech in Arizona
Biotechnology Forum
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] DuPont Announces New Biotechnology Advisory Panel Member

DuPont Announces New Biotechnology Advisory Panel Member
Thursday July 28, 11:45 am ET

WILMINGTON, Del., July 28 -- DuPont today announced the addition of
Mr. Chebet Maikut to its external Biotechnology Advisory Panel. Mr.
Maikut is the president of the Uganda National Farmers Federation
(UNFFE), one of the largest farmer organizations in Uganda. He joins
the ranks of seven other distinguished panel members who bring
important and diverse viewpoints to the broad area of biotechnology
and its application in agriculture, food and bio-based materials.
"Chebet Maikut's knowledge of African agriculture will provide
valuable insight into biotechnology policy and acceptance from the
perspective of a developing country and market," said DuPont
Chairman and CEO Charles O. Holliday, Jr. "He brings a strong voice
that represents both African opinions on biotechnology as well as
prospective customer segments in this emerging market."

As a farmer in the Kapchorwa District, Uganda, Maikut is no stranger
to the challenges facing African growers. He has dedicated his
career to empowering others to create a better quality of life
through the development of a sustainable African agricultural
industry. In addition to his role at the UNFFE, Maikut holds several
other leadership positions, including vice president, Eastern Africa
Farmers Federation (EAFF) and member of the Interim Panel of Eminent
Experts to the Global Crop Diversity Trust. He is also an active
participant of the CGIAR Sub-Saharan Challenge Program.

Formerly, Maikut was chairman of the International Federation of
Agricultural Producers' Committee on Science and Technology; a
District Councilor, Constituent Assembly (CAD) and a member of
Parliament (MP) in the National Assembly of Uganda representing
Kween in the Kapchorwa District. Before then, he worked with the
Republic of Uganda Ministry of Agriculture Animal Industry and
Fisheries (MAAIF).

Established in 2000, the DuPont external Biotechnology Advisory
Panel is an independent panel charged with providing counsel to
guide DuPont's actions, help create positions on important issues,
as well as challenge the organization in the development, testing
and commercialization of new products based on biotechnology.

In addition to Maikut, the other panel members include:

-- Dr. Marcelo Carvalho de Andrade, an accomplished advocate of
sustainable community development and environmental
preservation and
restoration. He is the founding chairman of Pro-Natura, the
first
international, nongovernmental organization headquartered in
the
Southern Hemisphere to specialize in sustainable development.
-- Professor Chunming Chen, founding president of the Chinese
Center for
Disease Control and Prevention and currently senior advisor
and
professor of nutrition. Professor Chen is an internationally
recognized expert in nutrition.
-- Dr. Pablo Eyzaguirre, senior scientist for anthropology and
socio-
economics in the Genetic Resources Science and Technology
group of the
International Plant Genetic Resources Institute (IPGRI)
based in Rome.
Dr. Eyzaguirre is a specialist in social and ecological
anthropology,
tropical farming systems, and agrarian institutions.
-- Father Kevin T. FitzGerald, S.J., Ph.D., research associate
professor
in the Department of Oncology at Georgetown University
Medical Center.
Father FitzGerald is internationally known and sought after
for his
expertise in human genetic engineering, cloning and stem cell
research.
-- Carol Tucker Foreman, well-known and respected consumer
advocate and a
distinguished fellow and director of the Consumer Federation
of
America's Food Policy Institute. Foreman has had a major
impact on
diet and health in the United States over the last 25 years.
-- Dr. V. Prakash, director of the Central Food Technological
Research
Institute (CFTRI) in Mysore, India. He is internationally
known for
his work in sustainable food and nutrition security. As a
scientist
in the area of biotechnology, Dr. Prakash has won a large
number of
awards and is a member of several international committees.
-- Dr. Sven Thormahlen, vice president of the Research and
Development
Organization of the Danone Group, a world leading company in
the field
of dairy products, biscuits and mineral water. Thormahlen's
experience covers product research, product development,
clinical
studies and quality assurance.

The work of the advisory panel is facilitated by the Keystone
Center, a non-profit organization based in Keystone, Colo., which
includes a regular audit of DuPont's progress in the biotechnology
arena. This public report is available at
http://www2.dupont.com/Biotechnology/en_US/difference/advisory.html .

DuPont is a science company. Founded in 1802, DuPont puts science to
work by creating sustainable solutions essential to a better, safer,
healthier life for people everywhere. Operating in more than 70
countries, DuPont offers a wide range of innovative products and
services for markets including agriculture, nutrition, electronics,
communications, safety and protection, home and construction,
transportation and apparel.

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Biotechnology Asia 2005 Expects 6,000 Trade Visitors

Biotechnology Asia 2005 Expects 6,000 Trade Visitors

KUALA LUMPUR, July 29 (Bernama) -- Biotechnology Asia 2005
Exhibition and Conference is expected to attract 6,000 trade
delegates, speakers, policy makers, industry professionals and
researchers who will gather to discuss opportunities and challenges
in the fast-booming biotech industry.

Conference organising chairman Dr Abdul Reezal Abdul Latif said last
year's event had received good response with 5,000 trade visitors
from 15 countries.

The exhibition this year will be held at the Putra World Trade
Centre (PWTC) here from August 16 to 18.

At a press conference here today, Abdul Reezal said 45 local and
international companies have confirmed their participation in the
exhibition which would showcase an array of products and services.

The inaugural Biotechnology 2005 Innovation Awards will also be
presented during the event.

http://www.bernama.com.my/bernama/v3/news_business.php?id=147517

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
5th Annual Biotechnology Educators Conference focused on food safety
North Texas e-News

5th Annual Biotechnology Educators Conference focused on food safety
By Janet K. Gregg, Texas A&M
Jul 24, 2005


"The positive confirmation of a cow in Texas with BSE and occasional incidents involving food contamination are examples of the need for continuing public and professional education on the topic of food safety. The Biotechnology Conference is a unique opportunity to gather all of the information and experts together to achieve that for educators.” – Rebecca Parker, Regional Program Director–ANR, Texas Cooperative Extension

� Who: Texas Cooperative Extension, Texas Agricultural Experiment Station, Texas A&M University, University of Texas Southwestern Medical Center at Dallas, University of Texas at Dallas, Collin County Community College and Region 10 Education Service Center



� What: Topics include: “Science, from Nobel to Neighborhoods”, “Ensuring Consumer Confidence in the Food/Fiber System”, “Biosecurity Issues: Food, Water & Animal Agriculture”, “Cloning Animals”, “Forensic DNA Analysis”, “The National Animal Identification System”, “Beastly Biotechnology” and “The Application of DNA Profiling”.


Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Women in Biotechnology Issues Invitation to 4th Annual Boston Breakfast Meeting

Women in Biotechnology Issues Invitation to 4th Annual Boston
Breakfast Meeting Aug. 9, 2005

Exciting Program Planned on Biotech Public Affairs Issues

The Boston Chapter of Women in Biotechnology issued an invitation
today to its 4th Annual Breakfast Meeting, which features three
prominent industry public affairs practitioners exploring the
theme, "Promoting Your Company's Agenda" regarding public affairs
issues. The speakers will reflect on how public affairs
professionals present company and industry positions on products,
reimbursement and legislative issues, and how to raise the money to
afford them. The meeting will be held on August 9, 7:30-9:30 AM at
the D'Arbeloff Suite at Boston's Museum of Science. Continental
breakfast and networking from 7:30-8 AM.

The meeting is sponsored by Thermo Electron Corporation, a worldwide
manufacturer of laboratory, analytical, measurement and control
instruments and software.

Program Speakers Will Explore Public Affairs Issues in Biotech

All three program speakers are respected public affairs
practitioners who will be imparting a wealth of knowledge on
product, reimbursement and legislative issues. The speakers are:

-- Janice Bourque, Senior Vice President, Comerica Incorporated

-- Susan Zagame Reardon, Esq., Director of Federal Affairs, Johnson
& Johnson

-- Janet Trunzo, Executive Vice President for Technology and
Regulatory Affairs, AdvaMed (Advanced Medical Technology
Association)

Meeting Registration Available Online

Register online for Women in Biotechnology's 4th Annual Breakfast
Meeting at www.womeninbiotechnogy.com. For questions, please contact
Kathleen Bernstein at kb@seidlerbernstein.com. On-site registration
will be accepted on a space-available basis, members, $50, non-
members, $80.

About Women in Biotechnology: Women in Biotechnology is a multi-
disciplinary, global coalition of women looking for an informal
setting to exchange ideas. Women in Biotechnology meets periodically
for informational, educational and networking sessions around events
relevant to our field. Women in Biotechnology founders are Kathleen
Bernstein of Seidler Bernstein, Inc.; Lena Chow of City of Paris,
Inc.; and Kathleen Dunn of KFDunn and Associates. In support of the
professional growth of their peers, the founders of Women in
Biotechnology encourage ongoing development of new leaders for the
group. To learn more, visit www.womeninbiotechnology.com.

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Prana Biotechnology Strengthens Board With Non-Executive Appointment

Prana Biotechnology Strengthens Board With Non-Executive Appointment
Friday July 29, 8:00 am ET

MELBOURNE, Australia, July 29 -- Prana Biotechnology Limited
(Nasdaq: PRAN, ASX: PBT), is pleased to announce the appointment of
Peter Marks as a non-executive director. Mr. Marks brings to Prana
extensive experience in the areas of corporate finance and advice
and venture capital investment, having specialized in capital
raisings (for listed and unlisted companies), underwritings and
initial public offerings in London and Australia.
Mr. Marks currently serves as Executive Chairman of Premier Bionics
Ltd., an investment company focused on investing in later stage
Australian-based research and development projects that demonstrate
strong commercial potential. He has served as an Associate Director
of McIntosh Securities, now Merrill Lynch Australia, as well as held
senior corporate finance positions at Barings Securities Ltd. and
Burdett Buckeridge & Young Ltd. in their Melbourne offices. In his
roles with these various financial institutions, he was responsible
for advising a substantial number of listed and unlisted companies
on issues ranging from corporate and company structure, to
valuations, business strategies, acquisitions and international
opportunities.

In addition, Mr. Marks has served as Head of the Melbourne Companies
Department at the Australian Stock Exchange; been a founding
Director of Momentum Funds Management Pty Ltd, an Australian venture
capital firm; and was employed by KPMG Corporate Finance Ltd
(Australia), where he rose to Director and was responsible for
heading up the equity capital markets group in Melbourne.

Geoffrey Kempler, chairman and CEO of Prana, said, "Peter brings
invaluable and highly relevant financial experience to the Board, as
well as wise counsel. His appointment brings to three the number of
non-executives on the Board. Peter will serve on the Audit
Committee, helping to maintain a high level of corporate compliance."

Mr. Marks holds a Bachelor of Economics, Bachelor of Laws and
Graduate Diploma in Commercial Law from Monash University in
Melbourne, Australia. He completed his MBA at the Scottish School of
Business at the University of Edinburgh.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into
Alzheimer's disease and other major age-related degenerative
disorders. The company was incorporated in 1997 and listed on the
Australian Stock Exchange in March 2000 and listed on NASDAQ in
September 2002. Researchers at prominent international institutions
including the University of Melbourne and Massachusetts General
Hospital, a teaching hospital of Harvard Medical School, discovered
Prana's technology.

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech shares up after Senate Majority Leader Bill Frist supports embryonic stem-cell research
Biotech share prices rise after Senate Majority Leader Bill Frist supports embryonic stem-cell research

Stock Market News and Investment Information | Reuters.com

Biotech shares up after Sen. Frist support
Fri Jul 29, 2005 9:12 AM ET

(Adds Geron, Aastrom, Stemcells)

NEW YORK, July 29 (Reuters) - Shares of three stem-cell research companies gained before the bell on Friday after U.S. Senate Majority Leader Bill Frist threw his support behind legislation to expand embryonic stem-cell research. [ID:nN29421279]

Shares of Geron Corp. (GERN.O: Quote, Profile, Research) were up 4.5 percent to $10.67 on the Inet electronic brokerage network, from a $10.21 close.

Aastrom Biosciences Inc. (ASTM.O: Quote, Profile, Research) rose 5.9 percent to $3.21 on Inet from their $3.03 close.

Stemcells Inc. (STEM.O: Quote, Profile, Research) jumped 10.7 percent to $5.79 on Inet from a close of $5.23. All three stocks trade on Nasdaq.



Health Books
Funny Quotes
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Magazine ranks New York No. 2 for biotechnology - 2005-07-26
Magazine ranks New York No. 2 for biotechnology - 2005-07-26

Magazine ranks New York No. 2 for biotechnology
Richard A. D'Errico
The Business Review
Gov. George Pataki touted the July issue of Business Facilities Magazine, which ranked New York No. 2 in the nation for developing biotechnology.




Recent Company News
» Business Facilities Magazine
Latest News
» Local Filene's to close following Federated/May merger
» Journal Register paying dividends
» Lawyer to address nanomedicine at World Future Symposium
» Daughters of Sarah names new CEO
» Intermagnetics revenue jumps 49 percent
More
» Companies in the News
» People in the News





Business Facilities is a magazine for companies seeking to expand or relocate their companies.

"The State's high ranking in this important industry magazine is yet another sign that our unprecedented efforts to promote high-tech, biotech and small tech research and economic development is returning major dividends," Pataki said. "The high technology we're creating today is helping to create the new jobs and economic growth of the future all across New York state."

Phoenix Arizona

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Biotech CEOs Seek SBA Fix to Continue Their Medical Research

281 Biotech CEOs Seek SBA Fix to Continue Their Medical Research

WASHINGTON, July 26, 2005

To demonstrate its support of H.R.2943 and S.1263, the "Save
America's Biotechnology Innovative Research (SABIR) Act," the
Biotechnology Industry Organization (BIO) today submitted a letter
to Congress endorsed by 281 biotechnology CEOs and senior executives
who are asking that this legislation be passed.

The legislation, introduced in the House by Sam Graves (R-Mo.) and
in the Senate by Kit Bond (R-Mo.), corrects the Small Business
Administration's (SBA) new interpretation of eligibility standards
related to Small Business Innovation Research (SBIR) grants.

The Rural Enterprises, Agriculture and Technology Subcommittee of
the House Small Business Committee is holding a hearing on the issue
at 2 p.m. Wednesday, July 27 in Room 2360 of the Rayburn House
Office Building. Douglas A. Doerfler, president and CEO of MaxCyte
Inc., of Gaithersburg, Md., will testify on behalf of BIO.

The SBA's action has forced many biotechnology companies to stop or
curtail research into therapies for many diseases, including HIV,
lupus, diabetes, leukemia, Alzheimer's and West Nile virus.

Presently, companies that are 51 percent owned by a group of venture
capital firms are not eligible for SBIR grants. Most small and
emerging biotechnology companies, which are years away from owning
revenue-generating drugs or biologics, must look to the venture
capital community for investments to fund the very high-cost
preclinical and clinical research.

"Prior to the SBA's new interpretation, many small biotechnology
companies relied on SBIR grants to validate the potential of their
research as they raised critical start-up investment funds," said
Jim Greenwood, BIO's president. "In submitting this letter, endorsed
by 281 CEOs -- many of whom run companies that have been impacted by
the new interpretation -- we urge Congress to support this new
legislation and re-start the flow of funds to innovative
biotechnology companies."

Doerfler and Morrie Ruffin, BIO's executive vice president of
capital formation and business development, discuss the impact of
SBIRs on the biotechnology industry during a BioLive Webcast for BIO
members. An excerpt can be viewed at
members.bio.org/biovideos/biolive_0705s.asx.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] New Report Examines Biotech Giant Amgen�s Success and Future Direction

New Report Examines Biotech Giant Amgen's Success and Future
Direction
Amgen is the world's largest biotechnology company and the eighth
largest pharmaceutical company worldwide, with revenues reaching $10
billion in 2004. Arrowhead Publishers' new report takes a detailed
look at the company's many successes and its strategy for the
future. (www.arrowheadpublishers.com/Amgen.html)

Minneapolis, MN July 26, 2005 -- Amgen is the world's largest
biotechnology company and the eighth largest pharmaceutical company
worldwide. Revenues have nearly doubled in the last three years,
going from $5.52 billion in 2002 to $10.55 billion in 2004. Yet the
majority of revenue is based on twenty-year old technology. Can
Amgen continue its amazing revenue growth? Or will it fall behind,
lacking the small molecule therapeutics that are the main stay of
modern pharmaceuticals?

Arrowhead Publishers' new report entitled "Amgen: Profile, Patents
and Pipeline" answers these important questions. It provides
detailed analysis and information concerning Amgen's business
activities. This report also includes a thorough accounting of the
company's patents and patent applications.

This report provides an in-depth analysis of Amgen's

• Strategic strengths and weaknesses
• Current therapeutic products and pipeline of future products
• Financial analysis, including R&D productivity
• Current patents and patent applications
• Alliances, joint ventures and acquisitions
• Key personnel

Who should buy this report?

• Biotech and pharmaceutical companies of all sizes interested in
understanding Amgen's rapid climb to success and its future
direction
• Early stage biotechnology companies interested in understanding
Amgen Ventures strategy for investing its $100 million
• Financial analysts looking for an in-depth technical analysis
of Amgen's future revenue sources

Key reasons to purchase this report

• Competitive intelligence
• Benchmark company performance against the leading biotechnology
company
• Understand what is driving Amgen's growth, and what is holding
it back

This 81 page up-to-date report, based on information gathered
through the end of the first quarter 2005, contains five tables on
Amgen's pipeline; a listing of the last three years of granted
patents, analyzed by therapeutic area as well as therapeutic form; a
breakdown of sales for all key products; both U.S. and
International, as well as a list of all patent applications for 2004
through the first quarter of 2005.

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Gurus Buy Biotech And Software, Trim Health Care - Forbes.com
Gurus Buy Biotech And Software, Trim Health Care - Forbes.com



Guru Picks
Gurus Buy Biotech And Software, Trim Health Care
John Dobosz, 07.26.05, 10:00 AM ET




NEW YORK - The Nasdaq Composite tacked on another 1.06% last week, again leading the gains of the S&P 500 Index (+0.47%) and the Dow Jones Industrial Average (+0.1%). Some of the biggest drivers of the Nasdaq's performance have been in the red-hot sectors of biotechnology and information technology, and that's where the best stock pickers at Marketocracy did most of their buying last week. Within tech, however, they favored software over hardware, a group within which they sold substantial positions to lock in profits.

Lock in yields of 12% and higher on Canadian energy royalty trusts. Click here for the top picks from Forbes/Lehmann Income Security Investor.
Three of the more significant new positions the M100 took last week were in biotech, where they bought genome mapping company Human Genome Sciences (nasdaq: HGSI - news - people ),drug developer Biogen Idec (nasdaq: BIIB - news - people ) and vaccine developer ID Biomedical (nasdaq: IDBE - news - people ).



http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications

Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for
Applications in the Research Products Market

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi
therapeutics company, announced today that it has granted MWG
Biotech AG, an established provider of synthetic nucleic acids, a
non-exclusive license to provide research products and services in
RNA interference (RNAi) under the Kreutzer-Limmer patent family
owned by Alnylam. This patent family covers short interfering RNAs
(siRNAs) and their use to mediate RNAi in mammalian cells.

"This agreement with MWG, an international genomic solution
provider, continues to highlight the value of the Alnylam-owned
Kreutzer-Limmer patent family as a critical component of fundamental
intellectual property in the field of RNAi," said Vincent Miles,
Ph.D., Senior Vice President, Business Development of Alnylam
Pharmaceuticals. "By leveraging our portfolio of leading IP, we are
creating value today and for the future by amassing an increasing
number of license agreements with leading reagent and service
providers. To date, fourteen companies have taken licenses for
therapeutic or research product applications, including eight
research product suppliers."

"This license strengthens our siRNA offering and is part of our
commitment to build a high quality presence in siRNA design and
production," said Dr. Wolfgang Pieken, CEO of MWG Biotech AG.

About RNA Interference (RNAi)

RNA interference, or RNAi, is a naturally occurring mechanism within
cells for selectively silencing and regulating specific genes. Since
many diseases are caused by the inappropriate activity of specific
genes, the ability to silence and regulate such genes selectively
through RNAi could provide a means to treat a wide range of human
diseases. The discovery of RNAi has been heralded by many as a major
breakthrough, and the journal Science named RNAi the top scientific
achievement of 2002, as well as one of the top 10 scientific
advances of 2003.

About Alnylam

Alnylam is a biopharmaceutical company seeking to develop and
commercialize novel therapeutics based on RNA interference, or RNAi.
Growing from its foundation as the world's first company focused on
RNAi therapeutics, the company's leadership in the field of RNAi is
supported by its preeminent founders and advisors and its strengths
in fundamental patents, technology, and know-how that underlie the
commercialization of RNAi therapeutics. Alnylam is developing a
pipeline of RNAi products using Direct RNAi(TM) to treat ocular,
central nervous system, and respiratory diseases and Systemic RNAi
(TM) to treat a broad range of diseases, including oncology,
metabolic, and autoimmune diseases. The company's global
headquarters are in Cambridge, Massachusetts. For additional
information, please visit www.alnylam.com.

About MWG Biotech AG

MWG Biotech AG (www.mwg-biotech.com) is an international provider of
DNA sequencing and DNA/siRNA synthesis products and services for
academic and industrial research from production sites in Germany,
the US, and India. With strong customer orientation, fast service
and high quality products the company creates the platform for
success in the life sciences today and for a better life tomorrow.
In its siRNA portfolio the company offers, in addition to a range of
siRNA products, a series of advance siRNA design tools and other
siRNA services.

Alnylam Forward-Looking Statements

Various statements in this release concerning our future
expectations, plans, prospects and future operating results
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important
factors, including risks related to: our approach to discover and
develop novel drugs, which is unproven and may never lead to
marketable products; our ability to obtain additional funding to
support our business activities; our dependence on third parties for
development, manufacture, marketing, sales and distribution of our
products; the successful development of products, all of which are
in early stages of development; obtaining regulatory approval for
products; competition from others using technology similar to ours
and others developing products for similar uses; obtaining,
maintaining and protecting intellectual property utilized by our
products; and our short operating history; as well as those risks
more fully discussed in the "Certain Factors That May Affect Future
Results" section of our most recent Form 10-Q filed with the
Securities and Exchange Commission. In addition, any forward-looking
statements represent our views only as of today and should not be
relied upon as representing our views as of any subsequent date. We
do not assume any obligation to update any forward-looking statements

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] The Sixth European Biotechnology Symposium November 13 - 15 2005

The Sixth European Biotechnology Symposium November 13 - 15 2005;
Competitive Biotechnology: Advanced Biologics Manufacturing and
Closing the Deal: Joint Ventures and Partnership

NEW ROCHELLE, N.Y. July 22, 2005--Sponsored by GENETIC ENGINEERING
NEWS and organized by BioConferences International, Inc., The Sixth
European Biotechnology Symposium at the Radisson SAS Scandinavia
Hotel in Copenhagen is the only event in Europe that assembles the
broadest collection of technical and business expertise from
Europe's rapidly-growing biomanufacturing sector.

GEN and BioConferences International will welcome all sponsors,
exhibitors and attendees at an opening reception in the expo hall on
the evening of Sunday, November 13, at the Radisson SAS Scandinavia
Hotel, Copenhagen.

The Symposium, which begins Monday, November 14, uniquely addresses
biotech's two principal concerns, technology and business, through
two consecutive tracks. "Competitive Biotechnology: Advanced
Biologics Manufacturing" (morning and afternoon, November 14 and
morning of November 15) features leading European experts in
biomanufacturing. Speakers include Dr. Prof. Florian Wurm (Swiss
Federal Institute of Technology, Lausanne) and representatives from
top biotechnology companies across Europe. "Closing the Deal: Joint
Ventures and Partnerships" (afternoon of Tuesday, November 15) will
provide a forum for business and finance experts to share their
expertise on partnership and funding activities which are critical
both to companies and the greater biotechnology industry.

Sponsors for the Sixth European Biotechnology Symposium include Host
Sponsor: Invest in Denmark, Chairs Cup: Pall Life Sciences,
Platinum: Sartorius, Diamond: Novozymes, Gold, Hyclone and Silver,
Stedim, CMC, and Linde. Additional sponsorships are available, as
well as a few non-commercial speaking opportunities.

Held approximately every other year, the European Biotechnology
Symposium has become a favorite stop on the European meeting and
conference circuit. This year's event promises even greater value
with the addition of "Closing the Deal". "This Symposium has been
extremely successful because speakers and attendees alike value the
intimate atmosphere and informative, non-commercial presentations,"
said Mary Ann Liebert, Publisher of Genetic Engineering News. "With
the addition of the 'Doing the Deal' session GEN and our partners
and sponsors hope to create a truly unique conference with broad
appeal to biotechnology scientists, engineers, and business
professionals."

For sponsorship information contact: HMatysko @ bioconferences.com
Harriet I. Matysko 914-740-2182.

registration: 914-740-2181 or 1 800 524 6266 Register on-line at
www.bioconferences.com/ebs.

BioConferences International Inc., New Rochelle

Biotech
Biotech News
Science Fairs
Entrepreneurs
High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Ag Biotech News Being Presented at AFBF Conference

Ag Biotech News Being Presented at AFBF Conference

http://www.fb.org/news/nr/nr2005/nr0629a.html

WASHINGTON D.C., June 29, 2005 – The AFBF Biotechnology Conference
will be held July 29 at the Indiana Farm Bureau headquarters in
Indianapolis.

"The conference is appropriate for anyone with an interest in the
current biotechnology situation in the United States and around the
world, as well as the outlook for agricultural biotechnology," says
Mark Maslyn, AFBF executive director of public policy.

There is no registrations fee for this national conference, but
those wishing to attend should email Donna Jackson at donnaj@fb.org
or call (202) 406-3679. For hotel accommodations the suggested hotel
nearby to contact is the Hampton Inn at telephone number 317-261-
1200.

Scheduled speakers include Cindy Smith, deputy administrator for
Biotechnology Regulatory Services under the Animal and Plant Health
Inspection Service of the Agriculture Department; Bobby Richey,
deputy director of the Foreign Agriculture Services Biotech Group at
USDA; Paul Green, international trade consultant; Barb Glenn,
director of animal biotechnology with the Biotechnology Industry
Organization; Michael Dykes, vice president, government affairs at
Monsanto; Jeff Stein, director of regulatory affairs at Syngenta
Seeds; and Mark Janis, professor of law at the University of Iowa
College of Law.

"First-hand, I know that our speakers have a great amount of
knowledge and information that they will share to enlighten
attendees," said Michelle Gorman, AFBF regulatory relations director
for biotechnology.

In general, topics being covered during the conference include
government regulations, non-food and feed uses for agricultural
biotechnology, animal biotechnology, ag biotechnology and trade,
technology fees and products in the pipeline.

Maslyn said, "Having the conference centrally located in the country
should make attendance easy and affordable for more of our members.
Additionally, the Indiana Farm Bureau office is an excellent meeting
facility."

Biotech
Biotech News
Science Fairs
Entrepreneurs
High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Science Fairs Information - Arizona Science Fairs. Science Fair Projects. Projects ideas and experiments - CARSEF - ISEF - NARSEF - AAISEF
Science Fairs Information - Arizona Science Fairs. Science Fair Projects. Projects ideas and experiments - CARSEF - ISEF - NARSEF - AAISEF
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Trinity Biotech Completes Acquisition of Primus Corporation

Trinity Biotech Completes Acquisition of Primus Corporation
DUBLIN, IRELAND --

07/21/2005 -- Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB.I), a
leading developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, today announced that
it has completed the acquisition of Primus Corporation, a leader in
the field of in vitro diagnostic testing for haemoglobin A1c and
haemoglobin variants.

Trinity Biotech has acquired Primus for US$12 million, consisting of
a cash consideration of US$9 million and a one-year promissory note
of US$3 million. The shareholders of Primus will also be entitled to
an additional consideration of up to US$4.6 million depending on the
growth of the business during the remainder of 2005. The transaction
is being funded entirely with bank borrowings, thereby leaving
Trinity's cash balances available for future potential acquisitions.

Primus, a Kansas City, Missouri based corporation advised by
Crosstree Capital Partners, was founded in 1989 and employs 36
people in the manufacture of glycohaemoglobin instruments and
reagents to serve customers from physicians' offices to the largest
reference laboratories worldwide. Trinity is committed to further
developing the business from the Kansas City location.

Primus has demonstrated consistent sales and profit growth. Sales
increased from $3.6 million for the year 2001 to $7.9 million for
the year 2004, a compound annual growth rate of 30%. The acquisition
will be earnings positive for Trinity Biotech in 2005. As part of
the transaction, Primus CEO and founder, Tom Reidy, will remain with
the Company and continue to direct the operations of Primus within
the Trinity Group.

Ronan O'Caoimh, Trinity Biotech CEO, commented, "We are delighted to
acquire Primus which has a strong track record of growth and a
unique patented technology in the field of A1c testing. In
particular, Primus has a strong position in the US market for
variant A1c testing with an estimated market share of 35%. Trinity's
distribution network through direct sales and worldwide distributors
can further expand the Primus sales effort and ultimately result in
a significant increase in the number of instruments placed above the
current level of approximately three hundred. We are also excited
about the new Primus Rapid Gel product which is currently awaiting
FDA approval which we expect will be granted in early 2006. The
Rapid Gel product will compete in the US$100 million point-of-care
A1c market and is based on the Company's unique boronate affinity
methodology. We are confident that Primus will make a significant
contribution to Trinity's growth in future years."

Tom Reidy, CEO and founder of Primus, commented, "The acquisition of
Primus by Trinity will provide the company with access to the wider
distribution base and technical support infrastructure of Trinity's
direct sales operations in the USA, Germany and the UK and to its
worldwide distributor network. We are very excited at the
opportunities this will present to continue the growth profile of
our business and to better serve our customers."

Trinity will provide additional information regarding the
acquisition during its second quarter earnings conference call on
Thursday 28th July at 11.00am EST.

Trinity Biotech develops, acquires, manufactures and markets over
500 diagnostic products for the point-of-care and clinical
laboratory segments of the diagnostic market. The broad line of test
kits are used to detect infectious diseases, sexually transmitted
diseases, blood coagulation disorders, and autoimmune diseases.
Trinity Biotech sells worldwide in over 80 countries through its own
salesforce and a network of international distributors and strategic
partners. For further information please see the company's website:
www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such forward-
looking statements involve risks and uncertainties including, but
not limited to, the results of research and development efforts, the
effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive
products, product development commercialisation and technological
difficulties, and other risks detailed in the Company's periodic
reports filed with the Securities and Exchange Commission.

---------------------------------------------------------------------
-----------

SOURCE: Trinity Biotech

Arizona Biotechnology
Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Rubicon Genomics Signs Agreement with the Genome Institute of Singapore for Retr

Rubicon Genomics Signs Agreement with the Genome Institute of
Singapore for Retrospective Studies of Serum

Serum Archive Converted to Valuable Genetic Resource to Fight
Hepatitis B

ANN ARBOR, Mich., July 21

Rubicon Genomics, Inc. today announced an agreement with the Genome
Institute of Singapore to use Rubicon molecular diagnostics
technology to recover genetic information from clinical serum
samples for a large study of the immune response to vaccination
against the hepatitis B virus.


The Genome Institute of Singapore (GIS) has chosen Rubicon to
isolate and amplify very small amounts of genomic DNA in archived
serum samples from 5,000 participants in a hepatitis B vaccine
trial. Later this year, GIS will use the amplified DNA in an
international study with colleagues in Indonesia and the Netherlands
to discover genes important for hepatitis B prevention and treatment.

"These DNA isolation and amplification methods were originally
developed for sensitive non-invasive screening for cancer from
patient serum and other fluids," said Dr. John Langmore, Vice
President of Commercial Development, Rubicon Genomics. "The
enthusiasm of our diagnostic partners has been noticed by
pharmaceutical companies and institutions, who want the same
sensitive, accurate, and repeatable results for clinical trials,
pharmacogenomics, drug discovery and epidemiology."

Modern genetic research and diagnostic tests require large amounts
of DNA from millions of cells; however, the most common clinical
samples such as serum and urine rarely contain these amounts of DNA.
The proprietary Rubicon technology efficiently isolates and
amplifies DNA from 10 - 100 cells -- making faithful copies
equivalent to millions of cells.

Rubicon is developing diagnostic tests capable of detecting the
presence of fewer than 10 cancer cells in less than three hours
using DNA or methylated DNA tumor markers. Amplified DNA from one
half milliliter of serum is sufficient for unlimited genetic or
epigenetic research assays. Rubicon uses these same technologies to
discover novel biomarkers, including DNA methylation markers that it
will use in more sensitive, specific and inexpensive tests for
cancer.

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, Mich., USA, develops and
commercializes proprietary OmniPlex(TM) technology for molecular
diagnostics and research. In projects with commercial partners,
Rubicon discovers novel methylation markers using microarrays and
uses them to develop more sensitive and specific non-invasive
diagnostic and prognostic tests for cancer from serum, urine and
biopsies. Rubicon also has large-scale contracts to amplify and
analyze DNA and RNA from sera and biopsies for pharmaceutical
companies, academic institutions, and tissue repositories. More
information can be found at http://www.rubicongenomics.com.

The Genome Institute of Singapore

The Genome Institute of Singapore (GIS) is a member of the Agency
for Science, Technology and Research (A*STAR). Established in 2001,
the research institute's mission is to be a world-class genomics
institute and a centre for genomic discovery. GIS pursues the
integration of technology, genetics, and biology towards the goal of
individualized medicine. The genomics infrastructure at GIS is
utilized to train new scientific talent, to act as a bridge between
academic and industrial research and explore scientific questions of
high impact. More information can be found at http://www.gis.a-
star.edu.sg and http://www.a-star.edu.sg.

Arizona Biotech
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
C&EN: Latest News - Roche Makes Biotech Buy
C&EN: Latest News - Roche Makes Biotech Buy

Roche Makes Biotech Buy
Deal for Swiss firm GlycArt nets antibody technology


PATRICIA SHORT


Roche has agreed to acquire GlycArt Biotechnology from a syndicate of private equity investors for approximately $180 million. GlycArt, a Swiss company with technology to enhance therapeutic antibodies for the treatment of cancer and autoimmune diseases, was founded in 2000 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich.

GlycArt and Roche have collaborated since September 2004 using GlycArt’s GlycoMAb technology, which increases the biological activity of therapeutic monoclonal antibodies for killing specific target cells implicated in disease. The technology works by engineering the carbohydrate components of the antibodies.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Biotechnology, Bioinformatics, Health Informatics and Health IT Jobs
Biotechnology, Bioinformatics, Health Informatics and Health IT Jobs
Biohealthmatics.com provides career resources and services for health informatics and biotechnology professionals and employers.




Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Arizona Biotech is now listed in Science > Biology > Biotechnology
Arizona Biotech is now listed in Science > Biology > Biotechnology in the Yahoo Directory
Arizona Biotech is now listed in Science > Biology > Biotechnology in the Yahoo! Directory


Arizona Biotech Yahoo! Directory - New Additions in Science for Thursday Jun 9, 2005

Directory > Science Directory > Biology > Biotechnology
Arizona Biotech -
includes news and information on Arizona Biotechnology, genomics,
biotech companies, genetic engineering, biotech research, and biology.

Arizona Biotech



http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
BioTech Medics Announces Sales of NeuroLase Medical Device and Grand Opening of Wellness Centers
BioTech Medics Announces Sales of NeuroLase Medical Device and Grand Opening of Wellness Centers
Thursday July 14, 9:30 am ET


DALLAS, July 14 /PRNewswire-FirstCall/ -- Keith Houser, CEO of BioTech Medics, Inc., (OTC Pink Sheets: BTMD - News) announced today the sale and delivery of the NeuroLase(TM) Therapeutic Medical Laser to the Laser Pain Center, LLC, in Boca Raton, Florida.
ADVERTISEMENT


The NeuroLase is one of the most powerful Class 3 B Medical Lasers cleared for the temporary reduction of muscle, skeletal or arthritic pain over the entire body.

Additionally, the Neurolase has been sold to a medical center in the Woodland - Sacramento, California area and should be opening by August 1.

Scripts Hospital in San Diego will be using the NeuroLase starting in August. Check the BioTech Medics web site for specific addresses and details.

A demonstration of the NeuroLase has been made to staff at Mount Sinai Hospital in South Miami Beach, Florida. A decision is expected soon.

"We are getting more calls from doctors around the USA desiring information about the NeuroLase. Patients who have benefited from being treated for pain relief with the NeuroLase are getting the word out as to the safe, drug-free and surgery-free therapy", said Mr. Houser. "With our ability to offer 95% financing, the decision for a medical practitioner to acquire the laser becomes easier."

For More Information Contact BioTech Medics at 972-274-5533 or on the Internet at: http://www.biotechmedics.com .

Safe Harbor for Forward-Looking Statements

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to have adequate financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing, and other risks described in various Company publications.

CONTACT: BioTech Medics, Inc., +1-972-274-5533

Web site: http://www.biotechmedics.com




--------------------------------------------------------------------------------
Source: BioTech Medics, Inc.

Marketing Firms - Search Engine Marketing Firms
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech firms fight pollution with plants
Globetechnology: Biotech firms fight pollution with plants

Biotech firms fight pollution with plants By PAUL ELIAS

Friday, July 15, 2005 Updated at 3:47 PM EDT

Associated Press

On the site of a former hat factory in Danbury, Conn., a stand of genetically altered cottonwood trees sucks mercury from the contaminated soil.

Across the continent in California, researchers use transgenic Indian mustard plants to soak up dangerously high selenium deposits caused by irrigation of the nation's bread basket.




Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Trypanosome genomes - Deadly Parasites Have Common Genetic Core - THE INSTITUTE FOR GENOMIC RESEARCH
Trypanosome genomes - Deadly Parasites Have Common Genetic Core

THE INSTITUTE FOR GENOMIC RESEARCH

Deadly Parasites Have Common Genetic Core;
Studies May Help Target New Drugs to Fight Them

Scientists decipher, compare the genomes of parasites that threaten
half a billion people, causing Chagas disease, Sleeping Sickness and
Leishmaniasis

One parasite causes a deadly sleeping sickness in Africa. The second
damages the internal organs of millions of Latin Americans. The
third causes terrible lesions on the face or limbs of victims from
Brazil to India.

The three parasites – the culprits behind African sleeping sickness,
Chagas disease and leishmaniasis – cause markedly varying diseases
and are carried by different insect vectors. But scientists have
found that the pathogens have a core of about 6,200 conserved genes.
Their genetic similarities far outweigh their differences.

"This common core of genes is extremely important because it may
provide targets for a new generation of drugs that might fight all
three parasites, which threaten millions of people worldwide," says
Najib El-Sayed, the first author of two of the parasite papers that
appear in the July 15 issue of Science and senior author of a third
paper. "At the moment, there are no vaccines and only a few
inadequate drugs to fight these devastating and neglected diseases."

El-Sayed is a molecular biologist at The Institute for Genomic
Research (TIGR), of Rockville, Maryland, which conducted the genome
sequencing and analysis along with scientists at the Wellcome Trust
Sanger Institute in Hinxton, U.K.; the Seattle Biomedical Research
Institute (SBRI); and the Karolinska Institutet, in Stockholm,
Sweden.

The Science issue includes several related papers, including genome
studies of Trypanosoma cruzi, which causes Chagas disease;
Trypanosoma brucei, which causes African trypanosomiasis, also known
as sleeping sickness; and Leishmania major, which causes the skin
disease leishmaniasis and an internal disease known as kala azar.
Another paper compares the three related genomes.
By determining the shared genes and focusing on those that differ,
the comparative study sheds important new light on the genetic basis
for the differences between the parasites – including how they
infect people, how they cause human disease, and why they are
carried by different insects. (T. cruzi is carried by blood-sucking
triatomine insects; T. brucei by the tsetse flies; and L. major by
sand flies.)

The comparison found dozens of genes found in all three parasites
that may have been acquired from bacteria through lateral gene
transfer. In addition, studies of the parasites' Variant Surface
Glycoproteins (VSGs) found T. brucei to have the most complex
genetic apparatus for avoiding host immune systems and, at the same
time, to be the most dependent of the parasites on the host's
metabolism. Scientists also discovered that many of the genes
specific to each species are found in so-called sub-telomeric
regions near the ends of chromosomes – areas where the genome tends
to be more changeable.

An important finding in the T. cruzi genome study was the discovery
of a novel and large set of 1,300 genes (called the "mucin-
associated surface protein," or MASP, genes) that may play a role in
the parasite's evasion of the human immune system or in its ability
to survive in the variety of hosts that it infects.

The T. cruzi project was funded by the National Institute of Allergy
and Infectious Diseases (NIAID), part of the U.S. National
Institutes of Health. The major funders of the T. brucei and L.
major genome projects were The Wellcome Trust and the NIAID.

Matthew Berriman of Sanger, the first author of the T. brucei genome
paper, predicts that the genome sequences will help advance research
into diseases that have been "neglected" in the past. "Genome
sequences allow ideas to be tested and more quickly turned into
reality," Berriman says. "The basic building blocks of all three
parasites are now known."

Peter J. Myler of SBRI, who shared the first authorship with El-
Sayed on two of the papers, says: "Now that the genes of these
parasites are mapped out, it's much easier to identify genes that
are critical for parasite survival. Genes encoding proteins that are
involved in critical biological processes often serve as drug
targets."

Much of the world's population in tropical and sub-tropical areas is
at risk of contracting one or more of the diseases. Chagas disease –
which may have infected Charles Darwin – infects as many as 18
million people and threatens about 100 million others in Latin
America, according to the World Health Organization. African
sleeping sickness (trypanosomiasis) infects between 300,000 and
500,000 persons and threatens more than 60 million people in 36
countries in sub-Saharan Africa. Leishmaniasis (which also can be
caused
by related parasites) is endemic in 88 countries and may threaten
as many as 300 million people.

*
* *

The Institute for Genomic Research (TIGR), which sequenced the first
complete genome of a free-living organism in 1995, is a not-for-
profit research institute based in Rockville, Maryland. TIGR
conducts research involving the structural, functional, and
comparative analysis of genomes and gene products in viruses,
bacteria, archaea, and eukaryotes.

[In addition to his faculty position at TIGR, Dr. El-Sayed also
holds an appointment in the microbiology and tropical medicine
department at the George Washington University School of Medicine in
Washington, D.C.]


Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Re: hello everyone

--- In biotech-news@yahoogroups.com, "samreen_btech"
<samreen_btech@y...> wrote:
> hello
>
> iam samreen doin my engg frm in biotechnology
>
> i just wanna know the top 100 universities offering biotech course
for
> ms in usa
>
> bubye

Here are a couple of places to start looking:

Arizona Biodesign Institute at Arizona State University

http://www.biodesign.org/

and the Institute for Biomedical Science and Biotechnology at
University of Arizona.

http://bio5.org/

Bill Austin
http://www.arizonabiotech.com/

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] hello everyone

hello

iam samreen doin my engg frm in biotechnology

i just wanna know the top 100 universities offering biotech course for
ms in usa

bubye

Arizona High Tech
Biotechnology Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Sonus Pharmaceuticals Sublicenses Non-Core Oxygen Delivery Patents to ImaRx Therapeutics
Sonus Pharmaceuticals Sublicenses Non-Core Oxygen Delivery Patents to ImaRx Therapeutics


Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) today announced that it has sublicensed intellectual property for fluorocarbon-based oxygen delivery applications to ImaRx Therapeutics, Inc. This oxygen delivery technology is not part of Sonus' core research, which shifted several years ago to the development of novel cancer drug therapies utilizing a vitamin E-based technology.


Under the sublicensing agreement, ImaRx will obtain exclusive rights to four patents covering Sonus' fluorocarbon technology, including both composition of matter patents and patents directed to methods of using the technology to deliver oxygen for therapeutic applications. Upon commercialization of any resulting products, ImaRx will pay a royalty to Sonus.

"We are pleased that we now have an opportunity to monetize our past investment in fluorocarbon technology, which had been an earlier business focus of Sonus. We are currently developing drugs for the treatment of cancer based on our TOCOSOL(R) vitamin E technology platform and are no longer pursuing the application of the fluorocarbon technology. However, we believe this technology is unique among approaches to oxygen delivery and has value for a company like ImaRx exploring a variety of potential applications in this field," said Michael A. Martino, President and CEO of Sonus Pharmaceuticals.

About Sonus Pharmaceuticals, Inc.

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related conditions. The Company's lead product candidate is TOCOSOL Paclitaxel, a novel formulation of the widely prescribed anti-cancer drug paclitaxel. TOCOSOL Paclitaxel has been designed to overcome the limitations associated with Taxol(R) and generic paclitaxel-based chemotherapy, including long infusion times, undesirable or treatment-limiting side effects as well as time consuming and expensive preparation of the products prior to administration. The U.S. Food and Drug Administration has completed a Special Protocol Assessment (SPA) for the pivotal Phase 3 trial of TOCOSOL Paclitaxel, which Sonus expects to initiate in 2005. For additional information about the Company, including news releases, please visit www.sonuspharma.com.

About ImaRx Therapeutics, Inc.

ImaRx, a privately held biopharmaceutical company, develops NanoInvasive(TM) therapies for the treatment of cardiovascular and CNS diseases, and cancers. The company's lead product, SonoLysis(TM), combines the power of ultrasound with proprietary nanobubbles to locally dissolve blood clots without the use of invasive surgery or potentially dangerous lytic drugs. SonoLysis is currently in a Phase II study for stroke and a Phase I/II study for peripheral arterial occlusive disease. For more information, please visit www.imarx.com.

Safe Harbor

Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products or the anticipated date of the initiation of Phase 3 clinical trials for TOCOSOL Paclitaxel. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 23, 2005, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the company will not be able to initiate Phase 3 clinical trials for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will not be successful; risks that the FDA may not approve the company's proposed New Drug Application; risks of successful development of additional drug delivery products; and risks that the company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Taxol(R) is a registered trademark of Bristol-Myers Squibb Company.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
ImaRx Launches NanO2 Nanobubble Therapeutics Program for Development of Portable Emergency Oxygen Treatments
ImaRx Launches NanO2 Nanobubble Therapeutics Program for Development of Portable Emergency Oxygen Treatments


July 11, 2005--ImaRx Therapeutics, Inc. announced today that it has launched its NanO2 Nanobubble Therapeutics program to develop portable emergency oxygen delivery treatments that will enable physicians to treat patients with hemorrhagic shock in the battlefield or other emergency situations. The program was developed around ImaRx's existing suite of oxygen delivery patents and advanced nanobubble emulsion technologies in addition to four U.S. patents that the company has exclusively sublicensed from Sonus Pharmaceuticals, Inc. The patents cover compositions of matter and methods of using oxygen delivery for treatment of disease.


"ImaRx has strengthened our existing oxygen delivery patent estate with several patents we sublicensed from Sonus. Combined with our expertise in developing specialized nanobubble formulations, the patents form the basis of our new NanO2 Nanobubble Therapeutics program," said Evan Unger, M.D., ImaRx's President and CEO.

Unger added, "We are currently evaluating the use of oxygen delivery nanobubbles to treat a variety of critical diseases and conditions including ischemia, shock and cancer. One of the most interesting potential applications of our NanO2 therapeutics is in replacing the bulky oxygen tanks military physicians currently use in the battlefield for treating patients who have experienced massive blood loss and are not getting enough oxygen to tissues in the body."

Claes Lundgren, M.D., Ph.D., professor of physiology and biophysics, SUNY-Buffalo, who is known for his invention of Nicorette gum and is an inventor of two of the Sonus patents sublicensed to ImaRx said, "Nanobubbles are highly efficient at oxygen delivery -- in fact 400 times more effective than red blood cells."

Dr. Lundgren presented results from studies in animal models at the American Heart Association's (AHA) Resuscitation Science Symposium in November 2004 showing that severe shock resulting from as much as 50 percent blood loss was treated completely effectively using very small doses of nanobubbles. The presentation was selected by the AHA as among the top ten percent given at the meeting.

Commenting on the study, Dr. Lundgren said, "The results from our study indicate that nanobubbles are a viable, completely synthetic alternative to blood substitutes. Because nanobubbles are made without potentially dangerous blood-based products and result in complete resuscitation both at very low doses of about 30 cc and without the use of supplemental oxygen, they may be ideal for use in emergency situations where a portable oxygen delivery treatment is required."

To treat hemorrhagic shock, a nanobubble emulsion is injected into the bloodstream where it expands into nanobubbles that circulate through the lungs. The nanobubbles imbibe and carry as much as 400 times more oxygen in the lungs than red blood cells and deliver it to poorly oxygenated tissues. Unlike other oxygen delivery therapeutics, chemical components of which can remain in the body for months or even years, remaining gas from the nanobubbles is quickly exhaled by the lungs.

About Sonus

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of therapeutic drugs that may offer improved administration, safety, tolerability and effectiveness for the treatment of cancer and related conditions. The Company's lead product candidate is TOCOSOL(R) Paclitaxel, a novel formulation of the widely prescribed anti-cancer drug paclitaxel. TOCOSOL Paclitaxel has been designed to overcome the limitations associated with Taxol and generic paclitaxel-based chemotherapy, including long infusion times, undesirable or treatment-limiting side effects as well as time consuming and expensive preparation of the products prior to administration.

About ImaRx and NanoInvasive Medicine

ImaRx, a privately-held biopharmaceutical company, develops NanoInvasive(TM) therapies for the treatment of cardiovascular disease, CNS disease, and cancers. The Company's lead product, SonoLysis(TM), combines the power of ultrasound with proprietary nanobubbles to locally dissolve blood clots without the use of invasive surgery or potentially dangerous lytic drugs. SonoLysis is currently in a Phase II study for stroke and a Phase I/II study for peripheral arterial occlusive disease. For more information, please visit www.imarx.com.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Japan External Trade Organization Sets Biotech Mission to Yokohama, Japan

Japan External Trade Organization Sets Biotech Mission to Yokohama,
Japan for September 4-10

CHICAGO, July 12
The Japan External Trade Organization (JETRO) has announced the
latest of its business-to-business missions to Japan, this one
supporting collaboration between North American and Japanese
biotechnology industries. Representatives from business, academia
and government on both sides of the Pacific will come face-to-face
to explore partnership opportunities during the bio-mission to
Yokohama, Japan, September 4 through 10.

During the BioMission, JETRO will provide companies and
organizations with opportunities to forge strong connections within
Japan's biotechnology sector. Mission activities include
participation in BioJapan 2005, one of Asia's largest biotechnology
trade shows, as well as the BioLink Forum 2005, a day- long event
where companies will gain insights on recent trends in the
biotechnology sector during sessions led by industry experts and
analysts.

More than 100 companies joined the inaugural BioMission to Japan in
2004, learning of the market, meeting with potential partners, and
for many, doing deals and realizing their goal of expanding to
Japan. The networking opportunities and business meetings from the
2004 BioMission has already led to solid business results for many.

"Japan's growing biotechnology market has made it very attractive
for U.S. companies seeking expansion and partnership. Japanese
biotech and pharmaceutical businesses have demonstrated a strong
interest in meeting with companies traveling with JETRO bio-
missions," commented Takashi Tsuchiya, Chief Executive Director of
JETRO's Chicago office. "We expect that companies participating in
this latest mission will experience an unprecedented introduction to
the Japanese market, leading to successful business development."

Pharmaceuticals, medical devices, chemicals and agri-bio form the
cornerstones of the Japanese market, and North American companies
and organizations are increasingly seeking ways to expand their
presence as Japan's market continues to grow. New business practices
in Japan, such as a shift from out-licensing to independent sales,
increased M&A activity, and a quicker drug approval process have
opened the way for new collaborations.

JETRO is subsidizing conference fees and expenses to provide mission
programming free of charge to mission members. Program includes:
BioLink Forum participation; BioJapan 2005 admission; business
matching; along with additional networking opportunities. JETRO is
arranging one-on-one meetings between mission members and Japanese
companies, however space is limited.

Application deadline for companies wishing to arrange one-on-one
meetings in Japan is Wednesday, July 20, 2005. The cost of this
mission is $905 US, excluding airfare. Mission space is limited.
Those interested in participating should contact Kelly Denewellis at
312-832-6000 ext. 203, or kelly_denewellis@jetro.go.jp. Additional
information can be found at http://www.jetro.org/biomission2005.

About JETRO

JETRO has provided information and support to American companies
entering the Japanese market for over 50 years. Through a local
network of six offices in the United States, JETRO provides a wide-
range of services, such as timely market intelligence, extensive
business development support, and relevant business events, all
designed to encourage business partnerships between American
companies and Japan. For information visit http://www.jetro.org.

---------------------------------------------------------------------
-----------
Source: Japan External Trade Organization (JETRO)

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] SRI International and European Bioinformatics Institute Significantly Expand

SRI International and European Bioinformatics Institute
Significantly Expand BioCyc Collection of Pathway/Genome Databases

SRI International, an independent, nonprofit research and
development organization, has significantly expanded its BioCyc
collection (biocyc.org/) of pathway/genome databases to now include
databases for 160 organisms. The BioCyc collection has grown from 18
to 160 organisms and now includes databases for most eukaryotic and
prokaryotic species whose genomes have been completely sequenced to
date.

The BioCyc pathway/genome databases contain information about
biochemical pathways: the network of interaction between proteins
and small molecules that forms the biochemical factory of a cell.
Understanding these pathways is critical in the development of
pharmaceuticals, which mostly operate by blocking or enhancing
interactions in particular pathways. The BioCyc collection is a
forum for the open sharing of this fundamental biological knowledge
that will have a significant impact on the future of biology.

Biomedical researchers are encouraged to adopt BioCyc databases for
organisms within their expertise for refinement and further
updating, and to redistribute those databases within the biomedical
research community. The process is akin to the development of
powerful open source software, leveraging the expertise of many to
create exponential progress in the human understanding of biology.

"No one group can curate all the world's genomes," said Peter Karp,
Ph.D., director of SRI International's Bioinformatics Research
Group. "It is imperative to involve many scientists in the updating
of genome databases. Ideally, BioCyc databases are adopted, and then
updated, by a group of scientists that share an interest in a
specific organism or a related group of organisms."

SRI collaborated with the Computational Genomics Group at the
European Bioinformatics Institute (EBI), a part of the European
Molecular Biology Laboratory, to add 142 new databases to the BioCyc
collection. Each pathway/genome database describes the genome and
predicted metabolic network of a single organism, as inferred from
the related SRI MetaCyc (metacyc.org/) database of metabolic
pathways from multiple organisms. BioCyc is a unique resource for
researchers in genomics, bioinformatics, and systems biology that
combines new information inferred from each genome with a powerful
collection of query and visualization tools.

"The combined use of a sophisticated software suite such as Pathway
Tools from SRI and a highly curated protein database such as
UniProtKB/SwissProt from the EBI has allowed the team to develop the
world's most comprehensive set of pathway databases," said Christos
Ouzounis, head of the Computational Genomics Group at the
EBI. "BioCyc provides both breadth and depth of coverage, enabling
researchers to put the vast body of data that has emerged from the
genome sequencing projects into the context of what gene products
are really doing in the cell. This type of work would have been
unthinkable even a few years ago."

To accelerate sharing of these databases once they have been
adopted, SRI has established a registry of pathway/genome databases
to allow scientists to register and share the databases that they
curate. The adoption and database-sharing approaches will maximize
the accuracy of the rapidly evolving knowledge about the genome and
biochemical networks of each organism. Most BioCyc pathway/genome
databases are openly available for updating and redistribution
without intellectual property restrictions. Adopters can update
adopted pathway/genome databases and publish them on their own Web
sites, using the same Pathway Tools
(bioinformatics.ai.sri.com/ptools/) software that powers the BioCyc
Web site.

BioCyc databases are organized into three tiers according to the
degree of curation they have undergone to date. For example, the
Tier 1 EcoCyc database (ecocyc.org) is a thoroughly curated
encyclopedia of E. coli (Escherichia coli K12) genes and metabolism.
Tier 2 pathway/genome databases have received moderate amounts of
curation, whereas Tier 3 pathway/genome databases were
computationally generated and received no curation.

BioCyc databases exist for most of the bacteria that are the
subjects of biodefense research, as well as bacteria that are being
studied for use in environmental remediation and the sequestration
of carbon from the atmosphere to reduce global warming.

BioCyc extracts new information from each of its component genomes
by predicting their metabolic pathways and, for bacteria, their
operons. Scientists use the Pathway Tools Omics viewer
(biocyc.org/ov-expr.shtml), available through the BioCyc Web site,
to visualize combinations of gene expression, proteomics and
metabolomics data on a wiring diagram for the metabolic network of a
cell. The software creates animated displays of time-series omics
data (a biological dataset derived from high-throughput
experimentation). Large and complex omics datasets become more
amenable to analyses when interpreted in the context of a cell's
pathway map. The BioCyc Web site also provides a newly released
genome viewer, and visualizations of operons and of individual
metabolic pathways.

Scientists interested in adopting a database should contact biocyc-
support@ai.sri.com. Most BioCyc databases are freely available to
users in both commercial and non-commercial institutions.

About the EBI

The European Bioinformatics Institute (EBI) is part of the European
Molecular Biology Laboratory (EMBL) and is located on the Wellcome
Trust Genome Campus in Hinxton near Cambridge (UK). The EBI grew out
of EMBL's pioneering work in providing public biological databases
to the research community. It hosts some of the world's most
important collections of biological data, including DNA sequences
(EMBL-Bank), protein sequences (UniProt), animal genomes (Ensembl),
three-dimensional structures (the Macromolecular Structure
Database), data from microarray experiments (ArrayExpress), protein-
protein interactions (IntAct) and pathway information (Reactome).
The EBI hosts several research groups and its scientists continually
develop new tools for the biocomputing community.

About EMBL

The European Molecular Biology Laboratory is a basic research
institute funded by public research monies from 18 member states
(Austria, Belgium, Denmark, Finland, France, Germany, Greece,
Iceland, Ireland, Israel, Italy, the Netherlands, Norway, Portugal,
Spain, Sweden, Switzerland and the United Kingdom). Research at EMBL
is conducted by approximately 80 independent groups covering the
spectrum of molecular biology. The Laboratory has five units: the
main Laboratory in Heidelberg, and Outstations in Hinxton (the
European Bioinformatics Institute), Grenoble, Hamburg, and
Monterotondo near Rome. The cornerstones of EMBL's mission are: to
perform basic research in molecular biology; to train scientists,
students and visitors at all levels; to offer vital services to
scientists in the member states; and to develop new instruments and
methods in the life sciences. EMBL's International PhD Programme has
a student body of about 170. The Laboratory also sponsors an active
Science and Society programme. Visitors from the press and public
are welcome.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the
world's leading independent research and technology development
organizations. Founded as Stanford Research Institute in 1946, SRI
has been meeting the strategic needs of clients for almost 60 years.
The nonprofit research institute performs contract research and
development for government agencies, commercial businesses and
nonprofit foundations. In addition to conducting contract R&D, SRI
licenses its technologies, forms strategic partnerships and creates
spin-off companies.

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech
News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona
Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>
<a href="http://www.arizonabiotech.com/index.php">Biotechnology News
Forums</a>

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Genentech - DNA - Avastin - Herceptin - Rituxan -Tarceva
Genentech - DNA - Avastin - Herceptin - Rituxan -Tarceva
MSN Money - Briefing.com Business News: Market Report -- Story Stocks (DNA, OSIP, BIIB): US:DNA

Genentech (DNA) 84.45 +0.95: The growth story continues for biotech giant Genentech. Amid ongoing clinical success, the world's second largest biotech company reported fiscal second quarter results well ahead of analysts' expectations. EPS climbed 58% from a year ago to $0.30, while operating revenues increased 35% to $1.53 billion. The results eclipsed the consensus estimates of $0.26 per share on revenues of $1.48 billion as strong sales of the company's cancer treatments broadly contributed to the upside.

Fast growing sales of leading products Avastin, Herceptin, Rituxan, and Tarceva have translated into healthy top line growth

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] 14th annual report: Top 100 biotechnology companies back to table of contents

14th annual report: Top 100 biotechnology companies back to table of contents

<a href="http://www.pharmalive.com/magazines/medad/view.cfm?articleID=2302">Med Ad News</a>

Over the Line: As the biotechnology industry outpaces traditional pharmaceuticals, the biotechnology leaders are taking top spots from big pharma peers. At the other end, small, emerging biotechnology companies struggle to find funding among risk-averse investors.

by Med Ad News Staff

Notes to Charts

Methodology

REVENUE: Top 100 biotechnology companies (table)

RESEARCH & DEVELOPMENT: Top 100 biotechnology companies (table)

EMPLOYEES: Top 100 biotechnology companies (table)

LOCATION, YEAR ESTABLISHED: Top 100 biotechnology companies (table)



As biotechnology companies merge and grow, they are rising in the ranks of the top companies overall. Traditional pharmaceutical companies, meanwhile, are partnering with the biotechnology sector to fill dry pipelines and to replace the dwindling blockbusters. Industry analysts believe that the growth of the biotechnology industry, led by Amgen Inc. and Genentech Inc., will continue to outpace that of pharmaceutical companies.

According to Wood Mackenzie analysts, the seven largest biotechnology companies are growing at rates faster than the pharmaceutical industry’s 9.1% average. Amgen is now ranked among the top 20 global pharmaceutical companies in the world and will break into the top 10 by 2008, Wood Mackenzie analysts say. In addition, five of the 10 largest mergers and acquisitions in 2003 were within the biotechnology sector, indicating continued growth and maturity.

"Our research shows what the industry has suspected: biotechnology companies have truly come into their own," says Jim Hall, life-sciences president, Wood Mackenzie (woodmac.com). "As biotechs increasingly retain ownership of their developmental compounds and create more targeted blockbuster drugs, they will grow faster than pharmaceutical companies."

Biotechnology companies will continue to take prominent positions among the top pharmaceutical companies, according to James A. Lebovitz, partner and chair, the business and technology group, Dechert LLP (dechert.com), and a member of Dechert’s health law group. "Right now, you can distinguish between the Pfizers and the Mercks, and the Amgens, Biogen Idecs, and Genentechs, but the distinctions are becoming fewer and fewer," he says. "As more biotech companies get bigger products that are just huge revenue generators, they will start to be mentioned in the same breath as those pharmaceutical companies."

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona
Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>
<a href="http://www.arizonabiotech.com/index.php">Biotechnology News
Forums</a>

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Substituting blood transfusions

Substituting blood transfusions
New research to substitute blood in transfusions
Do you have a rare blood group or are you concerned about
contracting a disease such as HIV from a blood transfusion? The
first ever European Blood Substitutes project
('EuroBloodSubstitutes') is designing molecules which will be able
to replace the need for blood during transfusions in the future.
Researchers are modifying the genes of the oxygen-carrying part of
the blood (haemoglobin) and using cell factories to mass produce
artificial molecules which will be able to oxygenate the body's
cells as efficiently, but without the possibility of contamination
with disease.
Dr Ken Lowe (University of Nottingham, UK) who is coordinating the
project says "We are using genomics to modify the haemoglobin as
well as looking at ways to attach it to large molecules so that it
stays in the body longer during transfusions. We are aiming to find
the optimum molecules for oxygen-binding and transport as well as
the best culture conditions for mass producing it for the future."
Dr Lowe will be reporting his results at the Society for
Experimental Biology Annual Meeting in Barcelona on Tuesday 14th
July [session E3.2].

This initiative is set to revolutionise blood transfusions which
will become largely safe especially in emerging countries such as
Eastern Europe and Africa where there are still relatively high
risks of contamination.

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona
Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>
<a href="http://www.arizonabiotech.com/index.php">Biotechnology News
Forums</a>

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
DNAPrint genomics Ticker Symbol Changing to 'DNAG'
DNAPrint genomics Ticker Symbol Changing to 'DNAG'
Monday July 11, 1:02 pm ET



DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced that commencing with the opening of the market on Tuesday, July 12, 2005, the Company's Common Stock will begin trading on the Over-the-Counter Bulletin Board under the symbol "DNAG."

The change of the symbol is the result of a stock consolidation approved by shareholders and the Board of Directors that also becomes effective the same day.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.



--------------------------------------------------------------------------------
Source: DNAPrint genomics
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Sigma-Aldrich (Nasdaq: SIAL) Announces New Organization to Accelerate Customers' Success and Growth
Sigma-Aldrich (Nasdaq: SIAL) Announces New Organization to Accelerate Customers' Success and Growth
Monday July 11, 5:54 pm ET


ST. LOUIS, July 11 -- Sigma-Aldrich announced today a new organization consisting of four customer-centric business units, each headed by a President reporting to the Company's President & COO, intended to further enhance its ability to serve its diverse base of more than sixty thousand commercial accounts comprising one million individual customers worldwide and the potential for above market growth rates.
After an extensive six month study which included interviews with nearly 650 customers around the globe, the Company is reorganizing its two existing life science and high technology Research businesses - Scientific Research and Biotechnology - into three units, each with its own distinctive competencies to meet the needs of carefully defined customer segments:


-- Essentials (20% of the Company's current sales), which will offer
customized account management to largely economic buyers in
pharmaceutical, academic and commercial research organizations, headed
by Gilles Cottier, 47, most recently Vice President - Sales. Cottier
joined Sigma-Aldrich in Lyon, France in 1986 and has served in a number

of positions of increasing responsibility including country manager for

France and Vice President - International Sales and Operations;

-- Specialties (35% of the Company's current sales), which will offer the
Company's traditional broad line of specialty products through its web
site and catalogs to lab scientists in these same accounts worldwide,
headed by David Julien, 50, most recently President - Biotechnology;
and

-- Biotech (20% of the Company's current sales), which will focus on
providing innovative, first-to-market research tools for life
scientists, headed by Shaf Yousaf, 45, most recently Vice President -
Corporate R&D and Biotechnology Marketing. Yousaf has helped launch
many of the Company's new initiatives in molecular biology and biotech
since bringing 13 years of experience with another leading global
biotech company to Sigma-Aldrich in 1996.


The Company's final business -- SAFC -- which stands separate from these Research units and represents 25% of the Company's current sales after the recent acquisition of JRH Biosciences, offers fine chemical products and flexible service solutions for customers in the three key industrial market segments of Pharma, Biosciences and Hi-Tech. SAFC will continue to be led by Frank Wicks, 52, who has served as the unit's President since January 2003.

Both Cottier and Yousaf will join Julien, Wicks, Chairman & CEO David Harvey, 66, President & COO Jai Nagarkatti, 58, and Chief Administrative Officer & CFO Michael Hogan, 52, as members of the Company's Executive Management Group.

While these organizational changes are effective immediately, the Company plans to continue to report its sales results for its three existing Scientific Research, Biotechnology and SAFC business units through 2005 and begin reporting under the new four-unit structure in 2006. Further details regarding the Company's goals, high-level strategies and growth initiatives for this new organization will be shared at its annual business review for shareholders and analysts on Tuesday, August 16, 2005 at 8:30 a.m. (Central Daylight Time). Information provided at that session will be simultaneously web cast over the Sigma-Aldrich website ( http://www.sigma-aldrich.com ). Details about how to access this web cast will be shared in a separate release. A replay will be available on the Company's web site until Tuesday, August 23, 2005.

Commenting on the new organization, President & COO Jai Nagarkatti said: "We're excited about our new organization and the opportunities its sharpened focus on meeting customers' needs is expected to provide for driving the potential for even better and more profitable growth. This latest change in our evolution towards a truly customer-centric company builds on the success of our past initiatives. Resting firmly on the base of historically profitable operations and a strong balance sheet, we believe this latest change and the strategies that support it should enable us to simultaneously excel in serving our customers, deliver 10% top and bottom line growth long-term for our shareholders and provide exciting and challenging opportunities for our employees."

About Sigma-Aldrich: Sigma-Aldrich (Nasdaq: SIAL - News) is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 35 countries and has over 6,800 employees providing excellent service worldwide. We are committed to accelerating Customers' success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning web site at http://www.sigma-aldrich.com .

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs. Although the Company believes its expectations are based on reasonable assumptions, such statements are subject to risks and uncertainties, including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied in this news release, due to, but not limited to, such factors as (1) changes in pricing and the competitive environment, (2) fluctuations in foreign currency exchange rates, (3) the ability to reinvest cash generated from operations in acquisitions and the impact of and success in integrating and obtaining projected results from such acquisitions, (4) other changes in the business environment in which the Company operates, (5) changes in research funding, (6) uncertainties surrounding government healthcare reform, (7) government regulations applicable to the business, (8) the impact of fluctuations in interest rates, (9) the effectiveness of the Company's further implementation of its global software systems and electronic ordering, (10) the ability to retain customers, suppliers and employees, (11) the success of research and development activities, and (12) changes in worldwide tax rates or tax benefits from domestic and international operations. The Company does not undertake any obligation to update these forward-looking statements.




--------------------------------------------------------------------------------
Source: Sigma-Aldrich Corporation


Biotech
Biotech News
Arizona Entrepreneur
High Tech
Biotechnology Forums

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Ceregene Adds Biotech Executive John Walker to Its Board of Directors
Ceregene Adds Biotech Executive John Walker to Its Board of Directors
Tuesday July 12, 7:00 am ET


SAN DIEGO, July 12 -- Ceregene, Inc. announced today that it has expanded its Board of Directors to 7 members with the election of John P. Walker as an independent Board member. Mr. Walker serves as an investment advisor to MDS Capital Corp and Executive Chairman of Guava Technologies. He also is vice-chairman of Renovis Inc and a Board member of Geron Corp. and several other private companies.
Mr. Walker brings over 30 years of biotechnology and pharmaceutical experience to Ceregene. His previous experience includes being Chairman and CEO of Bayhill Therapeutics; Chairman of Intramed, (now part of Baxter); Chairman and Interim CEO of Centaur Pharmaceuticals, (now part of Renovis Inc.); Chairman and CEO of AXYS and its predecessor company Arris Pharmaceutical, (now part of Celera); Chairman of Signal Pharmaceutical, (now part of Celgene); Chairman and CEO of Vitaphore Corporation, (now part of Union Carbide); Chairman of Microcide Corporation; and President of The Hospital Company of American Hospital Supply Corporation.

"Ceregene's refined focus on the delivery of nervous system growth factors using a gene therapy delivery platform and their accomplishments to date make them a very exciting company and I am pleased to join their Board and help further their advancement as they continue their clinical trials in neurodegenerative disorders," stated John Walker.

"We believe that Mr. Walker's vast experience in all aspects of biotech company development, from start-ups to product licensure and sales, will complement our current strong Board of Directors," stated Jeffrey M. Ostrove, Ph.D., Ceregene's president and CEO and director. Mr. Walker will join the current Board whose members include its chairman, Stephen A. Sherwin, M.D., chairman and CEO of Cell Genesys, Dennis Henner, Ph.D. of MPM Capital; David Mack, Ph.D. of Alta Partners, Eugene Step, past president of the pharmaceutical division of Eli Lilly and Mark Tuszynski, M.D., Ph.D., professor of neurosciences, University of California, San Diego.

Ceregene, Inc. is a San Diego-based biotechnology company focused on the development of gene therapies for neurodegenerative disorders. Ceregene is in the clinic with CERE-110, an AAV2 based vector expressing nerve growth factor that is being tested as a treatment for Alzheimer's disease. CERE-120 for Parkinson's disease has regulatory approval and will be tested in the clinic shortly and CERE-130 is in late preclinical development for ALS. Ceregene was launched in January 2001 and is a minority-owned subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE - News), which is headquartered in South San Francisco, CA. Ceregene closed a $32M Series B financing in August 2004 that was co-led by Alta Partners and MPM Capital.


Chicken Recipes
World Famous Recipes
Biotech
Biotech News
Arizona Entrepreneur
High Tech
Biotechnology Forums
Chicken Recipes
Cash Advances
Famous Recipes
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Visual Numerics(R) and Aegis Help Major Pharmaceutical and Biotech Companies

Visual Numerics(R) and Aegis Help Major Pharmaceutical and Biotech
Companies Optimize Manufacturing Processes, Save Millions of Dollars
Visual Numerics' IMSL(TM) C Numerical Library Brings Unrivaled
Analytical Power to Aegis Discoverant GlobalVantage(R) Solution for
Process Manufacturing Intelligence and FDA Compliance

SAN RAMON, CA -- 07/12/2005 -- Visual Numerics Inc., a leading
provider of numerical analysis and visualization software, announced
today that Aegis Analytical Corporation, a provider of enterprise
software and expertise for pharmaceutical and biotechnology
manufacturers, will utilize its IMSL C Numerical Library more
extensively to help major pharmaceutical and biotechnology companies
better monitor, analyze and manage their pharmaceutical
manufacturing practices to prevent costly mistakes.

Pharmaceutical manufacturing can be a high-risk process, in which
one unexpected deviation on the production line can cost a company
millions of dollars. Monitoring manufacturing operations require
that hundreds of key process parameters are tracked continuously,
resulting in a generous amount of data that must be monitored and
analyzed to ensure consistent quality. Aegis is embedding Visual
Numerics' IMSL C Numerical Libraries into its flagship product,
Discoverant, a suite of software products that enable pharmaceutical
and biotech companies to obtain direct access to all the data
collected from multiple locations throughout the manufacturing
enterprise -- in a framework that allows decision-makers to quickly
translate data into usable intelligence.

By using Visual Numerics' IMSL C Numerical Libraries as a part of
Discoverant, users will gain powerful analytical capabilities to
improve process monitoring and predictability, reduce manufacturing
downtime and waste as well as resolve and prevent compliance issues.
Companies today are saving millions of dollars by using Discoverant
with the IMSL C Numerical Library to pinpoint the exact factor
responsible for the success or failure of their manufacturing
processes.

"The Visual Numerics' IMSL C Numerical Library is an important
component of our Discoverant product suite, which provides the
reliability, scalability and validation our customers need to
optimize their drug manufacturing processes and comply with
regulatory standards," said Justin Neway, chief science officer,
Aegis Analytical Corporation. "The breadth of algorithm coverage
from the Visual Numerics IMSL C Libraries and ease of integration in
our application development, allows us to respond to market needs
quickly."

"Application developers in Life Sciences are increasingly turning to
Visual Numerics to meet their most data-intensive computational
needs," said Phil Fraher, president and CEO of Visual Numerics. "By
incorporating our 'gold standard' analytic capabilities, developers
save significant development time and costs while offering their
customers the very best analytical tools to navigate easily through
extremely complicated numerical environments."

IMSL™ Numerical Library Product Family

The IMSL™ Numerical Libraries have been the cornerstone of high-
performance computing and predictive analytic applications in
science, technical and business environments for over three decades.
Regarded as the most sophisticated, flexible, scalable and
accessible technology available in the most important mainstream
programming environments today, the IMSL Libraries provide users
with the software and technical expertise needed to develop and
execute advanced numerical analysis applications. The IMSL Libraries
save development time by providing pre-written mathematical and
statistical algorithms that can be embedded into C, C# for .NET,
Java™, and Fortran applications, significantly impacting return on
investment and programmer productivity.

About Aegis Analytical Corporation

Aegis Analytical Corporation provides manufacturing software and
expertise that helps pharmaceutical and biotech companies improve
compliance, increase profits and gain competitive advantage.
Discoverant, an enterprise software application, gathers data from
multiple sources and quickly transforms it into useable
intelligence. More information about Aegis Analytical Corporation
can be found at www.aegiscorp.com. For a streaming video demo
of Discoverant, visit: www.aegiscorp.com/product/demo.asp.

About Visual Numerics®

Visual Numerics has provided technical software solutions for
numerical analysis and visualization for more than three decades.
The company's software products help users understand complex data
from a variety of sources and build business-critical applications.
Visual Numerics offers two product lines: the IMSL Numerical
Libraries for powerful mathematical and statistical analysis and the
PV-WAVE® visual data analysis development environment. Visual
Numerics also offers customized professional services for
applications that involve mathematical, statistical, or visual data
analysis to meet today's business analytical needs.

Major corporations, academic institutions, and research laboratories
worldwide use Visual Numerics' software tools, including such high-
profile companies as: Bear, Stearns & Company; Barclays Global
Investors; Priceline.com; Humana, Sandia National Laboratories; and
Boeing Company. This large and diverse customer base is supported
through a direct sales force, wholly owned international
subsidiaries, and international distributors. For more information
about Visual Numerics, please visit www.vni.com.

Trademark Statement

Visual Numerics and PV-WAVE are registered trademarks of Visual
Numerics, Inc. in the U.S. and other countries. IMSL, JMSL, JWAVE,
TS-WAVE and Knowledge in Motion are trademarks of Visual Numerics,
Inc. All other company, product or brand names are the property of
their respective owners.

http://www.arizonabiotech.com/
<a href=="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href=="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href=="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href=="http://www.azhttp.com/">Arizona High Tech</a>
<a href=="http://www.arizonabiotech.com/index.php">Biotechnology News Forums</a>

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech Crops Reach Billionth Acre
Biotech Crops Reach Billionth Acre

Ten years ago, U.S. farmers planted crops produced from
biotechnology for the first time. The first genetically engineered
crops carried genes that allowed them to survive certain herbicides
to provide farmers more economical weed control options that
required less soil tillage and were better for the environment.
Since then, biotech crops have been introduced which are resistant
to major plant diseases and some of the most crop-damaging insects.

2005 Marks Ten Year Anniversary of Biotech Crops

June 2005
Ten years ago U.S. farmers planted crops produced from biotechnology
for the first time. The first genetically engineered crops carried
genes that allowed them to survive certain herbicides to provide
farmers more economical weed control options that required less soil
tillage and were better for the environment. Since then, biotech
crops have been introduced which are resistant to major plant
diseases and some of the most crop-damaging insects.

Today, an estimated 75 percent of the processed foods consumers buy
from grocery store shelves contain at least one ingredient resulting
from a biotech crop. And consumers can find high-quality,
unblemished biotech vegetables and fruits -- ranging from insect-
resistant sweet corn to disease-resistant papaya -- in the produce
aisle.

While providing consumers a safe and more abundant food supply,
biotech crops have become the most rapidly adopted technology in
agriculture's history. Now, a decade later, the one-billionth acre
of biotech crops is maturing somewhere in the world. It's an apt
time to look at some of the ways biotechnology is impacting the
world's food and fiber supply.

When the U.S. Department of Agriculture (USDA) releases its 2005
Crop Production Acreage Report at 8:30 a.m. Eastern on Thursday,
June 30, biotech crops -- including corn, soybeans and cotton -- are
expected to have continued expanding their share of crop acres as
the technology has each year for the past decade. Report to be
available at:
http://usda.mannlib.cornell.edu/reports/nassr/field/pcp-bba/

At their commercial introduction, proponents of biotech said the
crops would boost productivity and help feed a growing world
population. Last year, for the first time, biotech crop area in
developing countries grew faster than in developed countries,
further indicating the important economic, health and social
benefits realized by small, resource-poor farmers.

Dr. Clive James, founder and chairman of the International Service
for the Acquisition of Agri-Biotech Applications, a non-profit
organization addressing global hunger and poverty through technology
transfer to resource-poor farmers, and Thandiwe Myeni, a small-scale
farmer growing insect-resistant biotech cotton in KwaZulu-Natal,
South Africa, can bring global perspective to the latest USDA
biotech crop report. For more information on how biotechnology is
providing a more economical and abundant food supply for the world,
while protecting the environment, go to www.isaaa.org

---------------------------------------------------------------------
-----------

Produced for Council for Biotechnology Information

Thandiwe Myeni, a biotech cotton farmer in KwaZulu-Natal, South
Africa explains how biotechnology has helped improve her farm's crop
yield.

Video: Biotech

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Peninsula biotech gets a boost
Peninsula biotech gets a boost - 2005-07-11

Peninsula biotech gets a boost
Laura Cutland
A prolific real estate developer is making a big dollar bet on the peninsula that could help ease a space squeeze for Silicon Valley's biotech industry.

British juggernaut Slough Estates plans to transform 1.3 million square feet of property in Mountain View and Redwood City into life science hubs in a move described by industry members as one of the most significant property transactions of its kind in years.

Slough purchased 726,000 square feet of property in Mountain View's Shoreline Technology Park and 623,000 square feet in Redwood City's Seaport Centre from Equity Office Properties Trust in a deal announced on June 30.

Demand for such biotech space between South San Francisco and Mountain View is high now,
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Arizona BioIndustry Association
Arizona BioIndustry Association next installation of their Breakfast Series beginning at 7:30 AM at the Phoenix Hyatt Regency Hotel. The topic will be "Robotics in Neurological Rehabilitation: The Kinetic Muscles Story," featuring guest speaker, Ed Koeneman, Chief Operating Officer, Kinetic Muscles, Inc. For additional information, please call 480-510-6899 or visit the website at http://www.azbioindustry.org/

Tuesday, July 12

biotech news
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Successful Large Scale Biotech Project Nearly Complete

Successful Large Scale Biotech Project Nearly Complete
Thursday July 7, 12:25 pm ET

ROCKVILLE, Md., July 7

Human Genome Sciences awarded their Large Scale Manufacturing
Facility process piping contract to Kinetics in February, 2004. The
project is located within the Belward Research Center in Rockville,
Maryland and will greatly increase Human Genome Sciences' capacity
for production of protein and antibody drugs discovered through
genomics-based research.

Piping systems in the contract scope include purified water, two WFI
loops, process, clean-in-place, clean steam, CIP chemicals, ethanol,
process vents and condensate, biowaste and process waste drains. The
$20 million contract is currently 99% complete.

Engineering design of process piping by Lockwood Greene Engineers
was released for construction in stages beginning in January and
completed in October 2004. Coordination and teamwork between the
owner, engineer, and construction manager Gilbane Building Company,
Kinetics and project trade contractors was phenomenal and key to the
successful completion of the project.

As with most projects undertaken by Kinetics, off-site
prefabrication was maximized to reduce over-crowding and trade
stacking in the field. This is particularly important on such a
large biotech project. Modeled isometric piping drawings issued to
Kinetics were field verified, submitted, and approved by the owner
before being prefabricated at Kinetics fabrication shop in New
Berlinville, PA. Kinetics' jobsite manpower eventually peaked at 128
pipefitters through UA Local #602, plus supervision, draftsmen,
QA/QC and management personnel.

In March, 2005 Kinetics was awarded the 2004 Trade Contractor Award
by Gilbane Building Company "In Recognition of Excellence in
Performance" on the HGS Large Scale Manufacturing Facility project.

About Kinetics: Kinetics is a global provider of process and
mechanical solutions to the electronics, biopharmaceutical and
general industries. Kinetics combines support equipment assembly,
design, global installation capability and on-going service and
support for complete process system installations around the world.
The company has 32 offices and over 3000 employees, located
strategically in high-technology areas where semiconductor fabs and
biopharmaceutical manufacturing facilities are built. Kinetics is
based in Union City, California. For more information, visit
http://www.kineticsgroup.com .

---------------------------------------------------------------------
-----------
Source: Kinetics

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Gatlinburg Cabins - Rentals
Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Active Biotech's New Share Issue Oversubscribed

Active Biotech's New Share Issue Oversubscribed
STOCKHOLM, Sweden, July 7, 2005

Active Biotech announces that, following the close of the
subscription period for its share issue of approximately SEK 169 M
(18 Million Euro), the issue was oversubscribed by 43 percent.98.5
percent of the shares offered, were subscribed based on subscription
rights. Shares offered, which were not subscribed with the support
of subscription rights, will be allocated proportionally to those
who have subscribed for shares beyond their subscription right.

Through the new share issue, the number of shares in Active Biotech
will increase by 5,623,426 to a total of 39,363,983 shares.

Active Biotech's new share issue will be concluded according to the
following time schedule:

Notification of possible allocation of shares without the support of
subscription rights on or about July 8

Payment for shares allocated without the support of subscription
rights on or about July 13

First day of trading in new shares on or about July 25

The conversion price for existing convertible debentures, issued in
December 2004, will as a consequence of current new share issue be
adjusted accordingly and hence amount to 38.39 SEK.

Active Biotech AB (publ)
Sven Andreasson President & CEO

Active Biotech AB is a biotechnology company focusing on research
and development of pharmaceuticals. Active Biotech has a strong R&D
portfolio with pipeline products focused on autoimmune/inflammatory
diseases and cancer. Most advanced projects are laquinimod, an
orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis, as well as
ANYARA for use in cancer immunotherapy with the primary indication
non-small cell lung cancer. Further key projects in clinical
development comprise the three orally administered compounds TASQ
for prostate cancer 57-57 for SLE and RhuDex(R) for RA.

Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46-19 20 00 Fax:
+46 46-19 20 50 www.activebiotech.com

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Gatlinburg Cabins - Rentals
Biotechnology News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
The Phoebe R. Berman Bioethics Institute
The Phoebe R. Berman Bioethics Institute

The Berman Bioethics Institute's mission is to prepare the nation's next generation of leaders in bioethics; to promote research at the intersection of ethics, law, medicine, and science; and to provide policy advice on bioethical issues to the government and the private sector. (Click here for more information)







News

Ethical Goals of Community Consultation in Research [Neal Dickert & Jeremy Sugarman]
American Journal of Public Health

Views of US researchers about informed consent in international collaborative research [co-authored by Nancy Kass]
Social Science & Medicine

Doctors and Interrogators at Guantanamo Bay [co-authored by Jonathan Marks]
New England Journal of Medicine

Can the world afford to save the lives of 6 million children each year?
The Lancet

US stem cell research progresses despite limitations
BMJ


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
School of Public Health at Johns Hopkins
School of Public Health at Johns Hopkins

Deadly Bird Flu Virus May Endanger People
(Yahoo! News, July 6, 2005)


Researchers Discover Gene that Determines Asthma Susceptibility by Regulating Inflammation
(JHSPH News, July 5, 2005)
Prostate Cancer Screen Test Flawed, Experts Say
(Reuters, July 5, 2005)
Meth Is Top Drug Problem for Most Counties
(MSNBC, July 5, 2005)
Bush Has Plan to Fight Malaria
(Seattle Times, July 1, 2005)
Canada is Drafting Regulations to Curb Bulk Drug Exports to U.S.
(New York Times, July 1, 2005)
Knowledge of Tuskegee Study Doesn’t Increase Medical Mistrust
(JHSPH News, June 30, 2005)
Moving Targets: Progress, and Problems, in Treating AIDS Around the World
(The Economist, June 30, 2005)

Senate Votes to Ban EPA Pesticide Tests on Humans
(Los Angeles Times, June 30, 2005)
Authorities Desperate to Get Guns Out of the Hands of Teens
(WJZ-TV, June 29, 2005)

Video

Maryland’s Environmental Health Infrastructure Needs Repair
(JHSPH News, June 28, 2005)
Tsunami May Have Spawned New Paralyzing Lung Disease
(Seattle Times, June 27, 2005)
Debate Over Vaccines, Autism Continues
(Yahoo! News, June 25, 2005)
Racial Gap Seen in Gay Sex HIV Rates
(Reuters, June 24, 2005)
Health Professionals Involved in Guantanamo Interrogations
(HealthDay, June 23, 2005)
Experts Warn of Future WMD Attack
(CBS News, June 22, 2005)
Study Questions Autism Statistics
(HealthDay, July 6, 2005)
Indonesia Struggles to Halt Polio's Spread as Cases Jump to 111
(Bloomberg News, July 5, 2005)
Television in the Bedroom May Hurt Child’s School Performance
(JHSPH News, July 4, 2005)
Albert Schweitzer Fellowship Video Receives Telly Award
(JHSPH News, July 1, 2005)
Mad Cow Case's Origin is Narrowed
(Houston Chronicle, July 1, 2005)
Whooping Cough Booster Urged for Teens
(Newsweek, July 1, 2005)
Study of Vietnam Outbreak Calms Fears
(Baltimore Sun, July 1, 2005)
Smoking May Increase Tuberculosis Risk
(HealthDay, June 30, 2005)
EPA: Compound in Teflon May Cause Cancer
(MSNBC, June 29, 2005)
Survey: Most Say Medicaid 'Very Important'
(CNN, June 29, 2005)
$5.1 Billion Would Save 6 Million Children
(JHSPH News, June 27, 2005)
Health Spending Soars for Obesity
(USA Today, June 26, 2005)
Experts: Mad Cow 'Minor' Health Concern
(Washington Post, June 25, 2005)
Postdoctoral Fellows Present Research Findings
(JHSPH News, June 24, 2005)
AMA to Seek Limits on Tanning, Video Games
(Washington Post, June 23, 2005)
Western and Japanese Diets Up Colon Cancer Risk
(Reuters, June 23, 2005)
Cellphones Take Up Driver Attention, Study Finds
(Reuters, June 22, 2005)

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Center for Biosecurity of UPMC - Bioterrorism, Biodefense, Public Health Preparedness
Center for Biosecurity of UPMC - Bioterrorism, Biodefense, Public Health Preparedness

The Clinicians' Biosecurity Network,

Report from the International Conference on Biosafety and Biorisks,


Atlantic Storm, an exercise simulating a bioterrorist attack on nations of the transatlantic community, was convened on January 14, 2005 and organized by the Center for Biosecurity of UPMC, Center for Transatlantic Relations of JHU, and the Transatlantic Biosecurity Network.


How to Lead with the Public's Trust and Help: A Manual for Mayors, Governors and Top Health Officials, guidance on anticipating and averting governing pitfalls that arise during epidemics.

Executive Government Positions of Influence in Biodefense: The Bio-Plum Book.

Taking the Measure of Countermeasures: Leaders’ Views on the Nation’s Capacity to Develop Biodefense Countermeasures. Gilfillan L, Smith BT, Inglesby TV, Kodukula K, Schuler A, Lister M, and O’Toole T. December 2004.

Atlantic Storm Portends Rough Seas for International Coordination.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Using the genomic shortcut to predict bacterial behavior

Using the genomic shortcut to predict bacterial behavior

---------------------------------------------------------------------
The common flea can carry Rickettsia felis bacteria in its cells

---------------------------------------------------------------------

How do you study a pathogen that can't survive outside its host's
cells? In a new study published in the open access journal PLoS
Biology, Hiroyuki Ogata and colleagues show that sequencing and
analyzing the genome of the bacteria Rickettsia felis provide
valuable insights into the biology and behavior of this
intracellular pathogen. The researchers discovered that the
parasitic bacterium has the standard large circular chromosome plus
two unexpected plasmids, small circular pieces of DNA that can
replicate on their own. This discovery may lead to novel techniques
for study. "The newly identified plasmids may become a basis of a
new tool, such as for efficiently producing rickettsial proteins,"
explains Ogata.

Other Rickettsia species include the pathogens responsible for
typhus and Rocky Mountain spotted fever. "Up to now, due to the lack
of appropriate genetic transformation tools for rickettsiae,
detailed molecular studies were difficult for these bacteria," says
Ogata. But with new tools and "because of the medical importance of
this group of bacteria, different teams of researchers are
sequencing the genomes of different species of Rickettsia felis. We
determined the genome sequence of Rickettsia felis, which is the
fourth Rickettsia genome completely determined." R. felis is the
only species known to have a plasmid.

Ogata and colleagues also made surprising discoveries about sexual
activity in these bacteria. The larger plasmid encoded proteins
typically associated with bacterial sex, called conjugation. The
researchers also observed pilli, the bacterial conjugation bridge.
Previously, researchers believed that intracellular bacteria did not
exchange genetic material with each other. But Ogata explains that
the new findings "forced us to change this static view."

In addition to conjugation, the researchers found evidence of other
mechanisms for the bacterium to reshuffle its DNA. The R. felis
genome encodes a large number of transposases, enzymes that cut and
paste chromosomal DNA, and bears traces of multiple types of mobile
gene elements and acquisition of genes from other, non-rickettsial,
bacteria.

The research demonstrates that genomic analysis can provide new
information about an organism efficiently. "Our study demonstrates
the importance of sequencing a bacterial genome, even if several
closely related genomes have been already determined. It is very
difficult to correctly forejudge the diversity of bacterial
genomes," Ogata says. "Thus we have to sequence more."

###
Citation: Ogata H, Renesto P, Audic S, Robert C, Blanc G, et al.
(2005) The genome sequence of Rickettsia felis identifies the first
putative conjugative plasmid in an obligate intracellular parasite.
PLoS Biol 3(8): e248.

CONTACT:
Hiroyuki Ogata
CNRS UPR 2589
31 Chemin Joseph Aiguier
Marseille, France 13402 Cedex 20
33-491-16-4548
33-491-16-4549 (fax)
Hiroyuki.Ogata@igs.cnrs-mrs.fr

Source: PLoS Biology (www.plosbiology.org)

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Millipore Acquires European Contract Testing Lab; Acquisition Adds Expertise in

Millipore Acquires European Contract Testing Lab; Acquisition Adds
Expertise in Virus, Mycoplasma and Bacteria Testing and Strengthens
Millipore's Growing Services Business

Millipore Corporation (NYSE:MIL) today announced it has completed
the acquisition of MicroSafe, B.V., for approximately $9.3M.
MicroSafe is a contract laboratory that develops assays and provides
a range of testing services to help leading European biotech and
pharmaceutical customers monitor for quality and compliance in the
drug manufacturing process. The company employs thirty professionals
and is based in Leiden, The Netherlands.

Martin D. Madaus, Millipore's Chairman, CEO and President noted: "We
are very pleased that MircoSafe is becoming part of Millipore. They
have a loyal client base and the expertise that will help us expand
the scope of service we offer to our biotech and pharmaceutical
customers, particularly in the area of virus and mycoplasma testing.
Their application knowledge will also help us accelerate development
of products and systems for rapid process monitoring."

Fathia Methnani, Managing Director of MicroSafe, B.V.,
commented: "With Millipore's market presence in Europe and
scientists and applications specialists in the field we will be able
to bring our services to more clients and we'll be able to expand
those service offerings." Ms. Methnani will continue to direct
MicroSafe operations.

MicroSafe, with annual revenues of $4 million, has received GMP and
GLP approvals and is currently expanding its capabilities to meet
growing customer needs.

About Millipore

Millipore is a leading bioprocess and bioscience products and
services company, organized into two divisions. The Bioprocess
division offers solutions that optimize development and
manufacturing of biologics. The Bioscience division provides high
performance products and application insights that improve
laboratory productivity. Millipore has a deep understanding of its
customers' research and manufacturing process needs, and offers
reliable and innovative tools, technologies and services. The
Company employs approximately 4,500 people worldwide and posted
revenues of $883 million in 2004.

For additional information on Millipore Corporation, please visit
its website at: www.millipore.com

Forward Looking Statements:

The matters discussed herein, as well as in future oral and written
statements by management of Millipore Corporation that are forward-
looking statements, are based on current management expectations
that involve substantial risks and uncertainties which could cause
actual results to differ materially from the results expressed in,
or implied by, these forward-looking statements. Potential risks and
uncertainties that could affect Millipore's future operating results
include, without limitation, foreign exchange rates; regulatory
delay in the approval of new therapeutics and their ultimate
commercial success; further consolidation of drug manufacturers;
competitive factors such as new membrane technology; lack of
availability of raw materials or component products on a timely
basis; inventory risks due to shifts in market demand; change in
product mix; conditions in the economy in general and in the
bioscience and bioprocess markets in particular; potential
environmental liabilities; the inability to utilize technology in
current or planned products due to overriding rights by third
parties; difficulties inherent in research and development
activities; and the risk factors listed from time to time in
Millipore's filings with the SEC.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] GPC Biotech Announces Phase 1 Trial Evaluating Satraplatin in Combination with T

GPC Biotech Announces Phase 1 Trial Evaluating Satraplatin in
Combination with TAXOTERE(R) in Patients with Advanced Solid Tumors
Opens for Accrual

MARTINSRIED/MUNICH, Germany and U.S. Research and Development
Facilities in WALTHAM/BOSTON, Mass. and PRINCETON, N.J.,

-- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index;
Nasdaq: GPCB) today announced that a Phase 1 study evaluating the
Company's lead drug candidate, satraplatin, in combination with
TAXOTERE® (docetaxel) in patients with advanced solid tumors has
opened for accrual. Satraplatin is currently in a Phase 3
registrational trial as a second-line chemotherapy treatment for
patients with hormone-refractory prostate cancer.

The Phase 1 study is an open label, single center study being led by
Lynn Van Ummersen, M.D. Assistant Professor and George Wilding,
M.D., Professor at the University of Wisconsin Comprehensive Cancer
Center (UWCCC), Madison, Wisconsin. The primary objectives of this
study are to assess toxicity, determine maximum tolerated doses, and
recommend Phase II dosage for this combination. The objective
response in those patients with measurable disease will also be
assessed. The study is expected to enroll up to 48 patients.

"I am excited to have the opportunity for the UWCCC to conduct this
clinical study to develop a treatment regimen combining satraplatin
and TAXOTERE," said Dr. Wilding. "The favorable safety profile and
clinical activity of satraplatin in several solid tumor types and
the proven efficacy of TAXOTERE in various cancers make this a
treatment regimen that has the potential to help many patients with
cancer."

"We are pleased to have Dr. Van Ummersen and Dr. Wilding run this
trial. They have extensive experience in conducting Phase 1 cancer
studies and the UWCCC is a leader in the oncology field," said
Marcel Rozencweig, M.D., Senior Vice President, Drug Development at
GPC Biotech. "This study is part of our strategy to initiate a
number of studies to explore the potential of satraplatin in
combination with other anticancer therapies and for the treatment of
other cancers beyond the initial indication of second-line hormone-
refractory prostate cancer."

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum
family of compounds. Over the past two decades, platinum-based drugs
have become a critical part of modern chemotherapy treatments and
are used to treat a wide variety of cancers. Worldwide sales of
these drugs exceeded $2.2 billion in 2004. Unlike the platinum drugs
currently on the market, all of which require intravenous
administration, satraplatin is an orally bioavailable compound and
is given as capsules that patients can take at home. An oral
platinum drug could offer key advantages, including ease of
administration and patient convenience, in a variety of
applications. Additionally, satraplatin is the only platinum-based
compound to have shown efficacy in a randomized clinical trial in
prostate cancer. Prostate cancer is the most common cancer among men
in the U.S. and Europe. The number of patients with this disease is
expected to increase with the aging population. As the disease
advances, patients are often treated with hormone therapy. Once
patients fail hormone therapy, becoming hormone-refractory, follow-
on treatment involves a limited number of options, including
chemotherapy. For patients who then fail first-line chemotherapy,
there are currently no approved second-line chemotherapy regimens.
Satraplatin is in a Phase 3 registrational trial -- the SPARC trial -
- as a second-line chemotherapy treatment for hormone-refractory
prostate cancer (HRPC). GPC Biotech has successfully completed a
Special Protocol Assessment with the U.S. FDA and has received a
Scientific Advice letter from the European regulatory authority, the
European Medicines Agency (EMEA). The FDA has also granted fast
track designation to satraplatin for this indication.

Phase 2 trials have been completed in HRPC, ovarian cancer and small-
cell lung cancer. Promising early clinical results have also been
shown when satraplatin is combined with radiation therapy, and a
Phase 1/2 study evaluating this combination in patients with non-
small cell lung cancer has been initiated. Additional studies
evaluating satraplatin in combination with other therapies in
various cancers are planned. Further information on satraplatin can
be found in the Anticancer Programs section of the Company's Web
site at www.gpc-biotech.com.

GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs. The Company's lead product
candidate -- satraplatin -- is currently in a Phase 3 registrational
trial as a second-line chemotherapy treatment in hormone-refractory
prostate cancer following successful completion of a Special
Protocol Assessment by the U.S. FDA and receipt of a Scientific
Advice letter from the European central regulatory authority, EMEA.
The FDA has also granted fast track designation to satraplatin for
this indication. Satraplatin was in-licensed from Spectrum
Pharmaceuticals, Inc. Other anticancer programs include: a
monoclonal antibody with a novel mechanism-of-action against a
variety of lymphoid tumors, currently in Phase 1 clinical
development, and a small molecule broad-spectrum cell cycle
inhibitor, currently in pre-clinical development. The Company is
leveraging its drug discovery technologies to elucidate the
mechanisms-of-action of drug candidates and to support the growth of
its drug pipeline. GPC Biotech also has a multi-year alliance with
ALTANA Pharma AG working with the ALTANA Research Institute in the
U.S., which provides GPC Biotech with revenues through mid-2007. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany). The
Company's wholly owned U.S. subsidiary has research and development
sites in Waltham, Massachusetts and Princeton, New Jersey. For
additional information, please visit the Company's Web site at
www.gpc-biotech.com.

This press release may contain projections or estimates relating to
plans and objectives relating to our future operations, products, or
services; future financial results; or assumptions underlying or
relating to any such statements; each of which constitutes a forward-
looking statement subject to risks and uncertainties, many of which
are beyond our control. Actual results could differ materially
depending on a number of factors, including the timing and effects
of regulatory actions, the results of clinical trials, the Company's
relative success developing and gaining market acceptance for any
new products, and the effectiveness of patent protection. There can
be no guarantee that the SPARC trial will be completed nor that
satraplatin will be approved for marketing in a timely manner, if at
all. In addition, there can be no guarantee regarding the results of
the satraplatin and TAXOTERE Phase I study. We direct you to the
Company's Annual Report on Form 20-F, as amended, for the fiscal
year ended December 31, 2004 and other reports filed with the U.S.
Securities and Exchange Commission for additional details on the
important factors that may affect the Company's future results,
performance and achievements. The Company disclaims any intent or
obligation to update these forward-looking statements or the factors
that may affect the Company's future results, performance or
achievements, even if new information becomes available in the
future.

TAXOTERE® (docetaxel) is a registered trademark of the sanofi-
aventis group.

For further information, please contact:

GPC Biotech
AG Fraunhoferstr. 20
82152 Martinsried/Munich, Germany

Martin Braendle
Associate Director, Investor Relations & Corporate
Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com

In the U.S.: Laurie Doyle
Associate Director, Investor Relations & Corporate
Communications
Phone: +1 781 890 9007 X267
usinvestors@gpc-biotech.com

Additional Media Contacts:
In the U.S.:
Euro RSCG Life NRP
Emily Poe
Phone: +1 212 845 4266
emily.poe@eurorscg.com

In Europe:
Maitland Noonan Russo
Brian Hudspith
Phone: +44 (0)20 7379 5151
bhudspith@maitland.co.uk

---------------------------------------------------------------------
-----------
Source: GPC Biotech AG

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Amazon Biotech, Inc. Announces the Appointment of Meir Spear, CPA as the Company

Amazon Biotech, Inc. Announces the Appointment of Meir Spear, CPA as
the Company's Internal Accountant

Amazon Biotech, Inc. (OTC Bulletin Board: AMZB - News), a
pharmaceutical company developing and producing a potential
immunomodulator drug, developed for use in the treatment of the HIV
virus, today announced that it has retained the services of Meir
Spear, CPA from the firm of Spear & Co. CPAs as Amazon Biotech's
internal accountant (not independent auditors).
Meir Spear received his Bachelors of Science in Accounting from
Touro College, NY. He has over 9 years of experience in public
accounting and 4 years of experience working for one of New York's
top 15 accounting firms, servicing the needs of large and small
businesses with their tax and accounting needs.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company,
primarily developing immune modulator drugs. AMZ 0026 is the
company's first such drug, to be used for the treatment of HIV/AIDS.
The company intends to initiate Phase I/II clinical studies of AMZ
0026 shortly, with an eventual goal of a joint venture with a major
pharmaceutical company in Phase III trials, or to seek to qualify
for the FDA Fast Track program to market. Amazon Biotech specializes
in natural plant pharmaceutical drugs and is focused on bringing
healthier pharmaceutical drugs to market. Additional information on
Amazon Biotech may be found at http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation
Reform Act of 1995. This press release contains forward-looking
information within the meaning of Section 21E of the Securities
Exchange Act of 1934, including statements regarding any potential
sales of products as well as statements that include the
words "believes," "expects," "anticipates," or similar expressions.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of Amazon Biotech, to differ materially
from those implied or expressed by such forward-looking statements.
Such factors include, among others, the risk factors included in
Amazon Biotech's reports filed with the Securities and Exchange
Commission under the Exchange Act. This press release speaks as of
the date first set forth above and Amazon Biotech assumes no
responsibility to update the information included herein for events
occurring after the date hereof.

You may register to receive Amazon Biotech's future press releases
and to be added to the Company's distribution list by visiting:
http://www.roiny.com/form.php.

Investor Relations Contact:
Andrea Costa Robert Giordano
ROI Group Associates, Inc. ROI Group Associates, Inc.
Phone: (212) 495-0200 x14 Phone: (212) 495-0200 x10
Fax: (212) 495-0746 Fax: (212) 495-0746
acosta@roiny.com rgiordano@roiny.com
http://www.roiny.com

---------------------------------------------------------------------
-----------
Source: Amazon Biotech, Inc.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In P

Human Genome Sciences Reports Results of Phase 2 Clinical Trial of
HGS-ETR1 In Patients With Non-Small Cell Lung Cancer

- Results support continued study of HGS-ETR1 in combination with
chemotherapy in non-small cell lung cancer -

Human Genome Sciences, Inc. (Nasdaq: HGSI - News) announced today
that the results of a Phase 2 clinical trial demonstrate that HGS-
ETR1 (mapatumumab) is well tolerated and can be administered safely
in patients with advanced non-small cell lung cancer (NSCLC).(1)
Stable disease was observed in a number of patients.

Data on 32 patients were presented yesterday in Barcelona, Spain, at
the 11th World Conference on Lung Cancer in a poster
entitled "Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human
Monoclonal Antibody to TRAIL Receptor 1) in Subjects with
Relapsed/Recurrent Non-Small Cell Lung Cancer." The trial, which was
conducted in the United States, was a multi-center, open-label study
to evaluate the efficacy, safety and tolerability of HGS-ETR1 in
patients with relapsed or refractory non-small cell lung cancer.(2)
Patients enrolled in the trial received 10 mg/kg doses of HGS-ETR1
administered as an intravenous infusion 21 days apart in the absence
of disease progression. The primary objective of the study was to
evaluate tumor response. The secondary objectives were to evaluate
the safety and tolerability of HGS-ETR1, and to determine plasma
concentrations of HGS-ETR1 for use in a population pharmacokinetic
analysis.

Patients participating in the study had previously received up to 7
different cancer treatment regimens (median of 3). The data
presented demonstrated that HGS-ETR1 was well tolerated, with no
patients discontinuing therapy due to drug-related toxicity, and
that HGS-ETR1 can safely be administered intravenously every 21 days
at doses of 10 mg/kg. No immunogenic responses were observed. Stable
disease was observed in 29% (9/32) of the patients treated, with 8
patients receiving at least 4 cycles of therapy. Plasma
concentrations in the NSCLC study population were within the range
expected based on previous Phase 1/2 experience.

F. Anthony Greco, M.D., a study investigator and Medical Director of
The Sarah Cannon Research Institute, Nashville, said, "The results
of the Phase 2 study of HGS-ETR1 in heavily treated patients with
advanced non-small cell lung cancer support further evaluation of
HGS-ETR1 in this indication in combination with chemotherapeutic
agents. Non-small cell lung cancer represents a significant medical
need. Fewer than half of the patients who are newly diagnosed with
non-small cell lung cancer are candidates for surgery. The majority
of these patients present with incurable locally advanced or
metastatic disease. (3-4) We look forward to continuing to evaluate
the potential of HGS-ETR1 in non-small cell lung cancer in
combination with chemotherapeutic agents."

David C. Stump, M.D., Executive Vice President, Drug Development,
said, "HGS-ETR1 is the subject of a broadening program of clinical
study. We are pleased to have available the results of the Phase 2
trial in patients with advanced non-small cell lung cancer. The data
presented demonstrate that HGS- ETR1 can be safely and repetitively
administered to these patients. We note that stable disease was
observed in a number of these very ill patients who had received
multiple regimens of anti-cancer therapy before entering the study
of HGS-ETR1. We recently reported the positive interim results of a
separate Phase 2 clinical trial of HGS-ETR1 in advanced non-
Hodgkin's lymphoma and look forward to presentation of the complete
results of that study at an appropriate scientific meeting later in
2005.(5) The results of an ongoing Phase 2 study in patients with
advanced colorectal cancer are also expected later this year.(6) In
addition, we continue to enroll patients into two Phase 1b trials of
HGS-ETR1 in combination with chemotherapy."

Human Genome Sciences, using genomic techniques, originally
identified the TRAIL receptor-1 and TRAIL receptor-2 proteins as
members of the tumor necrosis factor receptor super-family. The
company's own studies, as well as those conducted by others, show
that TRAIL receptor 1 and TRAIL receptor 2 play a key role in
triggering apoptosis, or programmed cell death, in tumors. Human
Genome Sciences took the approach of developing human monoclonal
antibodies that would bind to specific TRAIL receptors and stimulate
the TRAIL receptor-1 and TRAIL receptor-2 proteins to trigger
apoptosis in cancer cells, in much the same way that the native
TRAIL ligand (tumor necrosis factor- related apoptosis-inducing
ligand) triggers it, but with the advantage of a longer half-life
and an exclusive specificity for TRAIL receptor 1 or TRAIL receptor
2, respectively. Human Genome Sciences' own clinical and preclinical
studies, along with published results in the scientific literature,
demonstrate that agonistic antibodies to the death domain-containing
TRAIL receptors have significant potential to provide novel
therapeutic options to patients with a variety of cancer types,
including non-small cell lung cancer.(7-26) The TRAIL receptor-1
agonistic human monoclonal antibody, HGS- ETR1, and one of the
company's two TRAIL receptor-2 human monoclonal antibodies, HGS-
ETR2, were made in a collaboration between Human Genome Sciences and
Cambridge Antibody Technology.(27) The second TRAIL receptor-2 human
monoclonal antibody, HGS-TR2J, was made in a collaboration with the
Pharmaceutical Division of Kirin Brewery Company, Ltd.(28-29)

Non-small cell lung cancer accounts for approximately 75-80 percent
of all lung cancers. It is estimated that more than 173,000 new
cases and more than 160,000 deaths of lung cancer occurred in the
United States in 2004. It is currently the leading cause of cancer
death in this country in both men and women.(3)

For more information about HGS-ETR1, see
www.hgsi.com/products/ETR1.html. Health professionals interested in
more information about trials involving HGSI products are encouraged
to inquire via the Contact Us section of the Human Genome Sciences
web site, www.hgsi.com/products/request.html, or by calling (240)
314-4400, extension 3550.

The mission of Human Genome Sciences is to discover, develop,
manufacture and market innovative drugs that serve patients with
unmet medical needs, with a primary focus on protein and antibody
products.

HGS and Human Genome Sciences are trademarks of Human Genome
Sciences, Inc.

This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The forward-looking statements are based on Human Genome Sciences'
current intent, belief and expectations. These statements are not
guarantees of future performance and are subject to certain risks
and uncertainties that are difficult to predict. Actual results may
differ materially from these forward-looking statements because of
the Company's unproven business model, its dependence on new
technologies, the uncertainty and timing of clinical trials, the
Company's ability to develop and commercialize products, its
dependence on collaborators for services and revenue, its
substantial indebtedness and lease obligations, its changing
requirements and costs associated with planned facilities, intense
competition, the uncertainty of patent and intellectual property
protection, the Company's dependence on key management and key
suppliers, the uncertainty of regulation of products, the impact of
future alliances or transactions and other risks described in the
Company's filings with the Securities and Exchange Commission.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. Human Genome Sciences undertakes no obligation to
update or revise the information contained in this announcement
whether as a result of new information, future events or
circumstances or otherwise.

Footnotes:
1. Bonomi P, Greco FA, et al. Results of a Phase 2 trial of
HGS-ETR1
(agonistic human monoclonal antibody to TRAIL receptor 1) in
subjects
with relapsed/recurrent non-small cell lung cancer. 11th
World
Conference on Lung Cancer. July 4, 2005. Abstract #1851.
2. (HGSI Press Release) Human Genome Sciences Completes Patient
Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the
Treatment
of Non-Small Cell Lung Cancer. November 30, 2004.
3. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics,
2004. Cancer
2004; 54(1):8-29.
4. Lara P, Lau DHM, Davies A, et al. Current Status and Future
Directions in Advanced Non-Small Cell Lung Cancer. Oncology
Special
Edition 2002; 4:129-135.
5. (HGSI Press Release) Human Genome Sciences Reports Interim
Results of
Phase 2 Clinical Trial of HGS-ETR1 in Patients with Advanced
Non-
Hodgkin's Lymphoma. June 13, 2005.
6. (HGSI Press Release) Human Genome Sciences Completes Patient
Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the
Treatment
of Colorectal Cancer. February 23, 2005.
7. Humphreys, RC. Development and evaluation of cancer
therapeutic
agents targeting TRAIL receptor 1 and 2. Cancer Drug
Discovery and
Development: The Oncogenomics Handbook (Ed.: La Rochelle
WJ and
Shimkets RA, Humana Press, 2005).
8. Younes A, et al. Activity of selective agonistic monoclonal
antibodies to TRAIL death receptors R1 and R2 in primary and
cultured
tumor cells of lymphoid origin. 9th International
Conference on
Malignant Lymphoma, 2005. Oral presentation.
9. Pacey S, et al. Phase 1 and pharmacokinetic study of HGS-
ETR2, a
human monoclonal antibody to TRAIL-R2, in patients with
advanced solid
malignancies. 2005 Annual Meeting of the American Society
of Clinical
Oncology (ASCO), Orlando, Florida. Abstract #3055.
10. Hotte SJ, et al. HGS-ETR1, a fully human monoclonal
antibody to the
tumor necrosis factor-related apoptosis-inducing ligand
receptor 1
(TRAIL-R1) in patients with advanced solid cancer: results
of a Phase
1 trial. 2005 Annual Meeting of the American Society of
Clinical
Oncology (ASCO), Orlando, Florida. Abstract #3052.
11. (HGSI Press Release) Human Genome Sciences Reports Results
of Phase 1
Clinical Trials of HGS-ETR2 and HGS-ETR1 in Patients with
Advanced
Solid Tumors. May 17, 2005.
12. Tolcher, et al. A Phase 1 clinical trial of HGS-ETR2, a
fully human
monoclonal antibody to TRAIL-R2 in patients with advanced
solid
tumors. 96th Annual Meeting of the American Association for
Cancer
Research, Anaheim, California, 2005. Abstract #543.
13. Mita M, et al. A Phase 1, pharmacokinetic (PK) study of HGS-
ETR1, an
agonistic monoclonal antibody to TRAIL-R1, in patients with
advanced
solid tumors. 96th Annual Meeting of the American
Association for
Cancer Research, Anaheim, California, 2005. Abstract #544.
14. (HGSI Press Release) Human Genome Sciences Reports Results
of Phase 1
Clinical Trial of HGS-ETR1 in Patients with Advanced Solid
Tumors.
April 18, 2005.
15. Halpern W, et al. Variable distribution of TRAIL Receptor 1
in
primary human tumor and normal tissues. 16th EORTC-NCI-AACR
Symposium
on Molecular Targets and Cancer Therapeutics, 2004:
Abstract #225.
16. Humphreys R, et al. HGS-TR2J, a human, agonistic, TRAIL
Receptor-2
monoclonal antibody, induces apoptosis, tumor regression and
growth
inhibition as a single agent in diverse human solid tumor
cell lines.
16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics, 2004: Abstract #204.
17. (HGSI Press Release) Human Genome Sciences Reports Results of
Preclinical Studies of TRAIL-R1 and TRAIL-R2 Agonistic Human
Monoclonal Antibodies at EORTC-NCI-AACR Symposium. October
1, 2004.
18. Georgakis GV, et al. Selective agonistic monoclonal
antibodies to the
TRAIL Receptors R1 and R2 induce cell death and potentiate
the effect
of chemotherapy and bortezomib in primary and cultured
lymphoma cells.
American Society of Clinical Oncology Annual Meeting, 2004:
Abstract
#6595.
19. Gillotte D, Zhang Y, Poortman C, et al. Human agonistic
anti-TRAIL
receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis
in
ovarian tumor lines and their activity is enhanced by taxol
and
carboplatin. Proceedings from the AACR 2004; 73:3579.
20. Humphreys R, et al. Novel, agonistic, human anti-TRAIL
receptor
monoclonal antibodies, HGS-ETR1 and HGS-ETR2, are capable of
potently
inducing tumor regression and growth inhibition as single
agents and
in combination with chemotherapeutic agents in models of
human NSCLC.
AACR-NCI-EORTC International Conference on Molecular Targets
and
Cancer Therapeutics. November 2003. Poster #B72.
21. Georgakis GV, Li Y, Humphreys R, et al. Activity of
selective
agonistic antibodies to TRAIL death receptors R1 and R2 in
primary and
cultured tumor cells of hematologic origin. Blood
2003;102:228a
(abstract #799).
22. Johnson RL, Huang X, Fiscella M. Human agonistic anti-TRAIL
antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in
diverse
hematological tumor lines. Blood 2003;102:981a (abstract
#3316).
23. Younes A, Kadin ME. Emerging applications for the tumor
necrosis
factor family of ligands and receptors in cancer therapy. J
Clin
Oncol 2003;21:3526-3534.
24. Pukac L, Kanakaraj P, Alderson R, et al. TRAIL-R1 mAb, a
human
agonistic monoclonal antibody to tumor necrosis factor-
related
apoptosis-inducing ligand receptor 1, induces apoptosis in
human tumor
cells in vitro and in vivo. American Association for Cancer
Research
94th Annual Meeting. July 2003, Abstract 6429.
25. Salcedo, Alderson R, Basu, et al. TRM-1, a fully human
TRAIL-R1
agonistic monoclonal antibody, displays in vitro and in vivo
anti-
tumor activity. American Association for Cancer Research
93rd Annual
Meeting. April 2002, Abstract #4240.
26. Humphreys R, et al. TRAIL-R1 and TRAIL-R2 human agonistic
monoclonal
antibodies display in vitro and in vivo activity on human
cancer
cells. Society for Biological Therapy 2002; oral
presentation.
27. (HGSI Press Release) Cambridge Antibody Technology and Human
Genome
Sciences Announce Second Drug Partnership. January 8, 2002.
28. (HGSI Press Release) Human Genome Sciences Initiates Clinical
Development of New Drug for the Treatment of Cancer. August
24, 2004.
29. (HGSI Press Release) Human Genome Sciences Announces Joint
Development
of Antibody for the Treatment of Cancer with Kirin.
December 3, 2002.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
The Complete Guide to Better Health
The Complete Guide to Better Health

The Complete Guide To Better Health program encompasses all aspects of health improvement. The information contained herein has been thoroughly researched over a fifteen-year time period. Composing a high-quality, health-enhancing program has been the author's most important project for the past five years.

The results of this research and practical application have produced an astonishing byproduct. The author, Wayne V. Dennis, N.C., at age forty-five, has three percent (3%) body fat, including a finely developed muscular frame. His skin is youthful and vibrant. His personality is considered cheerful and upbeat. He's had to visit a physician and a dentist only once in the past eighteen years. He rarely encounters illness.


Health News


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Arizona Biotech Funding News
Arizona Biotech Funding News

AmpliMed Secures $5 Million Series B Financing

TUCSON, Arizona

AmpliMed, Amplimexon and Amplizone are United States trademarks of
AmpliMed Corporation.

Oncology Drug Development Company to Use Funds to Develop and Expand
Portfolio of Anti-Cancer Therapies and Bring Drugs into Clinical
Trials

AmpliMed Corporation today announced the completion of a Series B
Preferred private placement of approximately $5 million. Led by
Biotech Insight Ventures, previous investors including InvestBio
Ventures, Valley Ventures and Solstice Capital also participated in
the round. To date, AmpliMed has raised more than $14 million in
financing.

"AmpliMed's impressive management team and outstanding group of
scientists have accomplished significant milestones in the research
and development of anti-cancer drugs, including the recent
initiation of Phase I/II clinical trials for its lead drug Amplimexon
(TM) for pancreatic cancer. We are delighted to participate again in
this second round of financing," said Joel R. Smolen, Managing
General Partner at Biotech Insight Management, L.L.C., which manages
Biotech Insight Ventures L.P. "The fact that our investors continue to support AmpliMed underscores their commitment to our clinical development program and
our pipeline of anti-cancer therapies. This is an exciting time for
the company as our Amplimexon(TM) clinical development program is
expanding rapidly and we plan to bring additional new drugs into
clinical trials in the near future," said Robert A. Ashley,
Chairman, President and Chief Executive Officer of AmpliMed. "This
funding will help us to continue these efforts as well as research
additional late-stage clinical development opportunities."

AmpliMed recently began a multi-center Phase I/II study to evaluate
the safety and effectiveness of a combination of gemcitabine and
Amplimexon in previously-untreated patients with advanced pancreatic
adenocarcinoma. Additional trials in patients with malignant
melanoma, multiple myeloma, breast, lung and prostate cancer are
planned in 2005.

About Amplimexon(TM)

Amplimexon is Amplimed's trademarked name for imexon injection, an
injectable formulation of a cyanoaziridine compound which showed
tantalizing evidence of activity in limited studies in lung cancer,
melanoma and breast cancer that were documented in publications in
the 1980s. The potential of imexon as a cancer drug was never fully
explored, until 1994, when AmpliMed co-founding scientists Drs. Evan
Hersh, David Alberts, Robert Dorr and William Remers initiated a
program to decipher Amplimexon's novel mechanism of action. They
discovered that the drug disrupted mitochondria, the energy
producing factories of the cancer cells, resulting in the leakage of
toxic substances which ultimately resulted in cell death. This led
to the initiation in 2003 of an ongoing Phase I clinical study of
the drug as a stand-alone therapy in late-stage cancer patients.
Further preclinical research revealed that the combined use of
Amplimexon and certain other chemotherapeutics resulted in a
significant increase in efficacy compared to either drug alone.
These findings are now being translated into a series of Phase I/II
clinical studies of combination therapy in patients with various
types of cancer.

About AmpliMed Corporation

AmpliMed Corporation was founded in 1989 with the support of the
University of Arizona Technology Development Corporation and is
focused on the clinical development of chemotherapeutic agents for
cancer. AmpliMed's strategy is to develop anti-cancer drugs with
novel mechanisms of action designed to overcome some of the
limitations, such as myelosuppression (suppression of blood cell
counts), multi-drug resistance (treatment-induced resistance to many
cancer drugs) and cardiac toxicity, frequently associated with
current cancer therapy. The company's lead product, Amplimexon(TM)
(imexon inj.), is undergoing NDA-directed clinical development.
Other products in the company's portfolio include Amplizone(TM),
which is anticipated to enter the clinic early in 2006, and a
portfolio of derivatives of both lead compounds for future
development. AmpliMed Corporation is based in Tucson, Arizona and is
on the Web at www.amplimed.com. AmpliMed, Amplimexon and Amplizone are United States trademarks of AmpliMed Corporation.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TGen�s Cancer Drug Discovery Laboratory Relocates to Mayo Clinic Collaborative R

TGen's Cancer Drug Discovery Laboratory Relocates to Mayo Clinic
Collaborative Research Building

Move enhances multidisciplinary environment, accelerates research

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research
Institute (TGen) today announced the transition of its Cancer Drug
Discovery Laboratory (CDDL) from their Gaithersburg, MD, facility to
the new Mayo Clinic Collaborative Research Building on the
Scottsdale campus of the Mayo Clinic. The CDDL was established as
TGen's drug discovery and development arm.
Co-locating CDDL and TGen's Drug Development (TD2) Services Unit
with researchers at the Mayo Clinic is a key component of TGen's
patient-centered research approach. The combination of world-class
researchers and the latest technologies creates a highly
collaborative multidisciplinary research environment, ensuring that
innovative preclinical research products will be moved from the lab
to the patient as quickly as possible. This will hopefully
ultimately improve and extend the lives of patients living with
cancer.

"The TGen-Mayo Clinic collaboration signifies a milestone, both in
terms of Arizona's leadership in bringing the best that biomedicine
has to offer to patients nationally and internationally and the
potential that research results between these two institutions will
have toward defeating cancer," said Sen. John McCain.

CDDL investigators are a multi-disciplinary team of scientists with
expertise ranging from cell biology to bioinformatics. The lab uses
a powerful cutting-edge technology called RNA interference (RNAi)
technology to accelerate their research. The area of RNAi opens up a
new field for drug discovery and will allow researchers to develop
specific and potent drugs. RNAi technology centers on understanding
how genes are turned on and off in cells and what the effect is on
those cells.

"The CDDL team has assembled some of the most sophisticated and high-
throughput technology in the world for studying cancer cells," said
Dr. Spyro Mousses, Director of CDDL. "Our RNAi technology should
greatly accelerate the discovery of new anti-cancer compounds."

The move to the Mayo Clinic Collaborative Research Building will
nearly triple CDDL's current capacity. The new building, which
officially opens its doors today, is an 110,000-square-foot facility
specifically devoted to developing and supporting medical research
that will help patients in Arizona and beyond.

"The CDDL's proximity to our researchers and clinicians accelerates
our joint pursuit of identifying strategies to defeat all forms of
cancer and further strengthens the Mayo Clinic mission of
integrating research and educational efforts with clinical medicine
to provide the best care for our patients," said Victor F. Trastek,
MD, Chair, Board of Governors at Mayo Clinic.

Mousses and his team are settling into the lab over the next few
months and will be completely moved in by early next year.

"CDDL's move to Arizona strengthens TGen's attack on cancer. The
addition of these researchers not only bolsters the translational
arm of TGen's discovery work, but proves that good science is
happening right here in Arizona, and with it comes the hope of
finding new ways to stop cancer in its tracks," said Dr. Jeffrey
Trent, TGen's President and Scientific Director.

# # #

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research
programs and its state-of-the-art bioinformatics and computational
biology facilities.

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ]TGen Drug Development Services

TGen Drug Development Services (TD2) Opens on Mayo Campus

TD2 integrates genomic technologies to advance drug development

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research
Institute (TGen) today announced the official opening of its drug
development services unit known as TD2. Located at the new Mayo
Clinic Collaborative Research Building on the Scottsdale campus of
Mayo Clinic, TD2 has over 10,000 square feet of wet and dry
laboratory space.
Advances in genomic discoveries and technologies are bringing in a
new era of personalized medicine, and in the process, transforming
the nature of drug development. TD2 is designed to integrate these
genomic advances with progressive drug development strategies aimed
at developing targeted therapies for patients with cancer.

"With more than 1,000 new drug candidates in development for cancer,
there is a tremendous need to bring the latest technologies to bear
on preclinical and clinical development programs," said Richard
Love, Managing Director TGen Accelerators. "TD2 expects to be on the
leading edge of utilizing genomic tools to guide the drug
development process and ultimately match the right drug with the
right patient."

TD2 helps investigators from research institutions, biotech and
pharmaceutical companies evaluate the efficacy of their drug
candidate by using preclinical models, genomic tools and
coordination of Phase I clinical trials at various clinical
facilities, including Mayo Clinic Scottsdale, Scottsdale Healthcare,
the Arizona Cancer Center, and U.S. Oncology. TD2 also provides
central coordination of an international team of investigators who
are conducting studies in patients with pancreatic cancer. Although
initially focused in oncology, TD2 expects to expand its
capabilities to other disease areas including neurological diseases
and diabetes.

TD2 is led by noted scientist and physician, Dr. Dan Von Hoff,
TGen's Director of Translational Research. "We are extraordinarily
fortunate to have the leadership of Dr. Von Hoff," said Steve Marsh,
General Manager of TD2. "He has led teams bringing more than 200 new
anticancer drugs into clinical development and has played a pivotal
role in getting many new anticancer drugs approved by the FDA."

###

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research
programs and its state-of-the-art bioinformatics and computational
biology facilities.

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TGen's Dr. Paul Keim Appointed to National Biosecurity Board

TGen's Dr. Paul Keim Appointed to National Biosecurity Board

Keim provides expertise on the genetics of weaponized pathogens

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research
Institute (TGen) today announced that Dr. Paul Keim, Director of the
institute's Pathogen Genomics Division, has been appointed to the
National Science Advisory Board for Biosecurity (NSABB), a group of
25 experts who will assess issues of biosafety in life sciences
research.
The NSABB will provide advice, guidance and leadership regarding
biological research that has the potential for misuse and could pose
a threat to public health or national security. The NSABB will
advise all federal departments and agencies that conduct or support
life science research.

"Dr. Keim's groundbreaking research with lethal biological agents
like plague and anthrax allows him to bring a unique perspective to
the board," said TGen President and Scientific Director Dr. Jeffrey
Trent.

"I am honored to serve my country by providing insight and expertise
about potential biological threats," said Dr. Keim.

In addition to his appointment at TGen, Dr. Keim is a professor of
biology and Cowden Endowed Chair in Microbiology at Northern Arizona
University (NAU). Keim and his NAU team are involved with protecting
America against anthrax and other dangerous microbes by analyzing
deadly agents that may be used in a biological attack at the genetic
level. The group is also developing molecular identification tools
for public health related pathogens, which cause illness in billions
of individuals worldwide.

Dr. Keim's nomination was supported by members of the Arizona
Congressional delegation, including Senators Jon Kyl and John
McCain, and Representatives Rick Renzi, John Shadegg and J.D.
Hayworth.

"It is a fitting tribute for Dr. Keim to be appointed to this
biosecurity board," said Senator Kyl. "The appointment is testimony
to Dr. Keim's work with pathogen genomics and his expertise will
help positively shape the future of public health policy. His
efforts on the NSABB will impact all of the nation, as well as
TGen's research efforts."

"Dr. Keim has done a phenomenal job of collecting and studying
biological threats from around the world," said Arizona Congressman
Rick Renzi. "His appointment to the NSABB will help keep America
safe and secure, and bring acclaim to Northern Arizona University."

# # #

About TGen
The mission of the Translational Genomics Research Institute (TGen)
is to make and translate genomic discoveries into advances in human
health. Translational genomics research is a relatively new field
employing innovative advances arising from the Human Genome Project
and applying them to the development of diagnostics, prognostics and
therapies for cancer, neurological disorders, diabetes and other
complex diseases. TGen is focused on personalized medicine and plans
to accomplish its goals through robust and disease-focused research
programs and its state-of-the-art bioinformatics and computational
biology facilities.

About Northern Arizona University
Northern Arizona University (NAU) has a student population of about
18,000 at its main campus in Flagstaff and at 30 sites across the
state. NAU has earned a solid reputation as a university with all
the features of a large institution but with a personal touch. NAU
carefully balances teaching, scholarship and service with a faculty
and staff dedicated to each student's success. While our emphasis is
undergraduate education, we offer a wide range of graduate programs
and research that extend to such national concerns as forest health

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] 5AM Solutions Grows Users by 5,000; Develops a D.C. Presence

5AM Solutions Grows Users by 5,000; Develops a D.C. Presence
An additional five thousand researchers studying neurological and
mental health disorders gained access to 5AM Solutions" Microarray
Enterprise Manager (MEM) this month. MEM provides researchers with a
tool to speed their access to microarray technology

Phoenix, Arizona June 29, 2005 -- An additional five thousand
researchers studying neurological and mental health disorders gained
access to 5AM Solutions" Microarray Enterprise Manager (MEM) this
month. MEM provides researchers with a tool to speed their access to
microarray technology available through the NIH Neuroscience
Microarray Consortium, and allows them to collaborate with other NIH-
funded researchers and the consortium"s Institutes of Excellence.
The Phoenix, Arizona-based 5AM Solutions also announced that the
firm has opened an office in the Washington, DC area to serve
clients and access their network of talent and contacts on the East
Coast.

In 2002, the National Institute of Neurological Disorders and Stroke
(NINDS) and the National Institute of Mental Health (NIMH) awarded a
grant to the consortium to make microarray technology available to
neuroscientists whose research was funded by the two institutes. At
that time, the consortium, which included the Translational Genomics
Research Institute (TGen), UCLA, and Duke University, needed
a "bridge" between it and scientists seeking to take advantage of
sophisticated technology that allows them to compare genes in normal
and diseased tissues. 5AM Solutions developed an internet-based tool
that manages workflow, collaboration, and communication between the
scientists and the consortium.

In June 2005, NINDS, NIMH, and thirteen other institutes that
comprise the NIH Neuroscience Blueprint
(neuroscienceblueprint.nih.gov/) awarded a $25 million grant to the
consortium which included funds to bring microarray technology to an
additional five thousand grant holders, added Yale University as a
Center of Excellence and renamed the consortium to reflect its
broader scope. 5AM Solutions Chief Architect Eric Tavela was pleased
to learn that the consortium would continue to use MEM and 5AM to
support their efforts. "Building a national, completely web-based
enterprise solution guided by leaders in the field of neuroscience
research and microarray technology was extremely rewarding." 5AM CEO
Brent Gendleman said, "Knowing that we contributed to their
management and informatics efforts and that they have been rewarded
with additional funding confirms that we are delivering quantifiable
return on investment."

Dietrich Stephan Ph.D., chairman of the consortium and director of
the Neurogenomics Division at the Translational Genomics Research
Institute (TGen), was enthusiastic about expanding access to the
consortium"s microarray technology. "The 5AM team has been dedicated
to serving the entire consortium from day one, enabling us to
collect, monitor and share our results and grant access to the
exciting technology and collective expertise to a national
audience."

5AM Solutions" new Northern Virginia office reflects the firm"s
growth. According to VP Operations Susan Mason, "Northern Virginia
is an ideal base for us to better serve our East Coast clients. We
are actively seeking teaming opportunities and have established
deals with GSA Schedule holders to make it easy for our target
clients to access our talent. There are ample opportunities for us
to apply our software development expertise to the wide range of
established industries – including the DC-area"s biotech market –
and use our software assets such as MEM to support customization
services."

About 5AM Solutions
5AM builds software solutions for the life sciences. Web-based,
interoperable solutions that integrate with third-party systems,
support industry guidelines and standards, and grant insight into
the complex data produced by the genomic revolution represent a core
of 5AM"s expertise. 5AM shares a common passion to advance medicine
and science by contributing state-of-the-art software engineering
services. www.5amsolutions.com

About the NIH Neuroscience Microarray Consortium
The Consortium is comprised of microarray core facilities at TGen,
UCLA, Yale, and Duke University. These institutes collectively
provide advanced microarray technology and other resources to
researchers who are committed to curing pervasive neurological and
mental disorders and diseases and whose work is funded by any of the
NIH Neuroscience Blueprint Institutes.
arrayconsortium.tgen.org

http://www.arizonabiotech.com/
Arizona Biotech
http://groups.yahoo.com/group/biotech-news/
Biotech News
http://www.arizonaentrepreneurs.com/
Arizona Entrepreneurs
http://www.azhttp.com/
Arizona High Tech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech